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Postpartum thyroiditis is a syndrome of transient or perma-
nent thyroid dysfunction occurring in the first year after de-
livery and based on an autoimmune inflammation of the thy-
roid. The prevalence ranges from 5–7%. We discuss the role of
antibodies (especially thyroid peroxidase antibodies), com-
plement, activated T cells, and apoptosis in the outbreak of
postpartum thyroiditis. Postpartum thyroiditis is conceptu-
alized as an acute phase of autoimmune thyroid destruction
in the context of an existing and ongoing process of thyroid
autosensitization. From pregnancy an enhanced state of im-
mune tolerance ensues. A rebound reaction to this pregnancy-
associated immune suppression after delivery explains the
aggravation of autoimmune syndromes in the puerperal pe-
riod, e.g., the occurrence of clinically overt postpartum thy-
roiditis. Low thyroid reserve due to autoimmune thyroiditis
is increasingly recognized as a serious health problem. 1) Thy-
roid autoimmunity increases the probability of spontaneous
fetal loss. 2) Thyroid failure due to autoimmune thyroiditis—
often mild and subclinical—can lead to permanent and sig-
nificant impairment in neuropsychological performance of
the offspring. 3) Evidence is emerging that as women age
subclinical hypothyroidism—as a sequel of postpartum thy-
roiditis—predisposes them to cardiovascular disease.
Hence, postpartum thyroiditis is no longer considered a
mild and transient disorder. Screening is considered.
(Endocrine Reviews 22: 605–630, 2001)
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I. Introduction
THE MOST FREQUENT and best characterized autoim-mune thyroid disease postnatally is postpartum thy-
roiditis. Postpartum thyroiditis is a syndrome of transient or
permanent thyroid dysfunction occurring in the first year
after delivery and based on an autoimmune inflammation of
the thyroid. Classically, a thyrotoxic phase is followed by a
hypothyroid phase (1). Several intrinsic and environmental
factors have been reported to play a pathophysiological role
in its development (2–6). “Postpartum” thyroiditis may also
occur after loss of pregnancy at 5–20 wk gestation (7–9).
The syndrome of hypothyroidism after pregnancy was
first described in 1948 by Roberton (10). Ginsberg and
Walfish (11) recognized the classical thyrotoxic phase pre-
ceding this syndrome of puerperal hypothyroidism, and
Abbreviations: ADCC, Antibody-dependent cell mediated cytotox-
icity; CTLA-4, cytotoxic T-lymphocyte antigen-4; hCG, human CG; IFN,
interferon; IVF, in vitro fertilization; MHC, major histocompatibility
complex; NK, natural killer; NOD, nonobese diabetic; PIBF, progester-
one-induced blocking factor; TBII, TSH binding inhibitory Igs; TH1 and
TH2, T helper 1 and 2; TPO, thyroid peroxidase; TSAb, thyroid stimu-
lating antibody; TSH-R Abs, TSH-receptor antibodies.
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Amino et al. (12) highlighted its clinical importance in the
1980s. Subsequently, the clinical awareness of this condition
has become widespread.
Postpartum thyroid syndromes distinct from postpartum
thyroiditis have also been identified and include postpartum
disturbances in thyroid function in patients with previous or
current thyroid disease (2, 3, 13) and postpartum secondary
hypothyroidism (14, 15). Combinations of these postpartum
thyroid syndromes, as well as combinations of preexisting
Graves’ disease and Hashimoto’s disease with postpartum
thyroiditis, have also been described (16–19).
II. Epidemiology of Postpartum Thyroiditis
The prevalence of postpartum thyroiditis varies widely,
from 1.1–21.1% (12, 20–38) (Table 1). This wide variation is
largely due to differences in the definition of postpartum
thyroiditis (39); on the other hand, variable and sometimes
inadequate ascertainment and follow-up play a role. Fur-
thermore, in some studies thyroid scintigraphy has been
omitted in some of the thyrotoxic patients, thus leading to a
possible underestimation of postpartum Graves’ disease.
Apart from these methodological considerations, environ-
mental and genetic factors in the population are thought to
play a role in the variability of prevalence data.
Only two studies, both from Europe, obtained end-point
data from more than 70% of the described source population.
These studies reported similar prevalences of 6.5% and 7.2%,
respectively (24, 30). Recent work from The Netherlands,
with a follow-up of 65% of the original cohort, reported a
prevalence of 5.2% (26). Nicolai et al. (29) reported a prev-
alence of 6.7% in a North American population with a fol-
low-up of 65%. Hence, the prevalence of postpartum thy-
roiditis in iodine-sufficient areas ranges between 5–7%.
In patients with type I diabetes mellitus, higher frequen-
cies of postpartum thyroiditis have been described. Gerstein
(40) performed a prospective cohort study of 51 pregnant
subjects with type I diabetes who were not taking thyroid
medication. Forty patients completed follow-up. Thyroid
dysfunction occurred in 10 patients: thyroiditis developed in
9 and Graves’ disease in 1 patient during the first 6 months
after delivery (40). Alvarez-Marfany et al. (41) followed 41
women with type I diabetes mellitus, 28 of whom completed
follow-up at 31 months postpartum: seven subjects devel-
oped thyroiditis. Thus, the incidence of postpartum thyroid-
itis in type I diabetes mellitus is at least 15%.
III. Thyroid Antibodies, Autoimmune Thyroiditis,
and Postpartum Thyroiditis
A. Thyroid peroxidase and thyroglobulin (Tg) antibodies
Postpartum thyroiditis is closely associated with the pres-
ence of antibodies to thyroid peroxidase (TPO) (12, 20, 21, 23,
24, 26, 27, 30, 34, 38) (Fig. 1). Indeed, if a pregnant women is
positive for TPO antibodies early in pregnancy, her chances
of developing postpartum thyroiditis are 30–52% (4, 42–44).
The first thyroid autoantigen discovered (1956) and shown
to play a role in Hashimoto’s thyroiditis was Tg (45). Later,
antibodies were detected to antigens present in the cyto-
plasm of thyroid follicular cells (46–49). In the 1980s these
“cytoplasmic” antigens were characterized as the enzyme
TPO (50–53). Antibodies to TPO appeared to be much more
prevalent than antibodies to Tg. When both antibodies are
present, the titer of TPO antibodies tends to be higher (46, 53,
54). The exclusive presence of Tg antibodies is rare. Thus, for
the routine detection of thyroid autoantibodies, it is justifi-
able to determine TPO antibodies only (55). In this respect it
is also notable that TPO antibodies—but not Tg antibodies—
can fix complement (56).
Evidence for a pathogenetic role of TPO complement-
fixing antibodies is circumstantial. Activation of the com-
plement cascade—an important mechanism for lysis of target
cells in immune processes—is associated with the IgG sub-
classes 1, 2, and 3 (57). With regard to postpartum thyroiditis
Parkes et al. (58) used both the complement fixation and
complement C3 activation index to quantify the interaction
of the complement system with thyroid antigen/antibody-
complexes. They studied 152 TPO antibody-positive women
and an equal number of TPO antibody-negative women.
Seventy-five of the TPO antibody positive women remained
euthyroid during the postpartum year, and 73 showed bio-
chemical signs of postpartum thyroiditis. The authors pro-
vided evidence that the onset and progression of thyroid
dysfunction in women with TPO antibodies was not only a
function of the titer of the TPO antibodies present, but also
of their ability to activate the complement system (58). Also,
in another study, the same authors showed that the severity
of postpartum thyroiditis, as indicated by the duration of
thyroid dysfunction, is related to the ability of TPO antibod-
ies to interact with and activate the complement system (59).
Regarding the IgG subclasses of TPO antibodies Jansson et
al. (60) found that the relative concentration of IgG1 TPO
antibodies was significantly increased in women who be-
came hypothyroid. Hall et al. (61) showed significant relative
elevations in IgG2- and IgG3-associated TPO antibody ac-
tivity in women who developed a biphasic thyroid dysfunc-
tion. The relative IgG3 elevation coincided with the onset of
thyrotoxicosis. Briones-Urbina et al. (62) found raised IgG1-
and IgG2-associated TPO activity and low IgG3-associated
TPO antibody activity in women with postpartum thyroid-
itis. However, Weetman et al. (63) found no differences in IgG
subclass-associated TPO antibody distribution between
women with postpartum thyroiditis and controls. Therefore,
at present, there is no agreement on the significance of the
subclass of TPO antibodies in postpartum thyroiditis. What
seems clear, however, is that the IgG4-associated TPO anti-
body activity—which is non-complement-activating—
remains unchanged in the postpartum period (60, 62, 63).
Although the association of TPO antibodies with postpar-
tum thyroiditis is strong, a causative role of these antibodies
in the pathogenesis of this syndrome remains unclear. In
Hashimoto’s thyroiditis, antibodies to TPO are thought to
play only a secondary aggravating role in addition to other
immune destructive mechanisms (6, 55) (Fig. 2). TPO anti-
bodies are indeed able to bind to thyroid follicular cells and
to activate the complement system and to set in motion
antibody-dependent cell mediated cytotoxicity (ADCC) (see
below). However, it is relevant to recall that: 1) TPO is only
expressed at the apical border of thyroid follicular cells in a
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position where it is hardly accessible to circulating antibodies
if the follicles are intact (64); 2) there is only a weak associ-
ation between complement-fixing thyroid cytotoxic antibod-
ies and hypothyroidism in chronic autoimmune thyroiditis,
these antibodies being found even in sera of euthyroid pa-
tients (56); 3) babies born to mothers with chronic autoim-
mune thyroiditis and circulating TPO antibodies have nor-
mal thyroid function (65); 4) circulating TPO antibodies are
found in sera of a consistent percentage of euthyroid elderly
women (66).
Bispecific antibodies with dual specificity for Tg and TPO
are also associated with autoimmune thyroid disease. Ini-
tially, these antibodies were reported not to be associated
with postpartum thyroiditis (67). However, in a recent mul-
ticenter study of 3,122 patients with various thyroid and
nonthyroid diseases and normal subjects, the prevalence of
these bispecific antibodies was 16% in subjects with post-
partum thyroiditis (68). In normal control subjects (n  220)
a prevalence of only 1.4% was found. The value of 16% in
postpartum thyroiditis was also significantly different from
FIG. 1. f, Prevalence of TPO antibodies in women with postpartum thyroiditis., Prevalence of TPO antibodies in women without postpartum
thyroiditis. An asterisk denotes that the TPO antibody prevalence is not given or cannot be calculated from the data. See Table 1 for details
of the studies.
FIG. 2. The various immune mechanisms leading to alterations in thyroid metabolism and growth: 1. Thyroid-specific antibodies ( ) e.g.,
TPO-antibodies, recognize their target-antigens (f) on the surface of thyrocytes. These antibodies may activate complement (C) or NK cells
via Fc receptors (the latter is the so-called ADCC). 2. Target antigens ( ) can also be recognized by CD8 T cytotoxic cells or CD4 TH1 cells
producing -IFN and IL-2. These cytokines have direct effects on thyrocyte growth and metabolism. -IFN is also able to activate macrophages
(M) to kill thyrocytes or to produce IL-1 and IL-6 influencing thyrocyte growth and metabolism. 3. Furthermore, antibodies directed to the
TSH-R either stimulate or block the receptor and coupled to the receptor various second messenger systems. This will either lead to stimulation
or blockade of thyrocyte growth and metabolism.
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levels found in patients with Hashimoto’s thyroiditis (40.5%)
and Graves’ disease (34.6%). Although these differences
were statistically significant, the clinical relevance of these
antibodies is at present unclear.
In conclusion, there is a strong association between the
presence of TPO antibodies and the risk of developing post-
partum thyroiditis. However, there are several good argu-
ments against a role of TPO antibodies as the primary dis-
ruptive event in the pathogenesis of postpartum thyroiditis.
B. TSH-receptor antibodies (TSH-R Abs)
The number of studies on the role of TSH-R Abs in post-
partum thyroiditis is limited. In a study from the United
Kingdom TSH-R Abs were found in none of 37 women who
experienced a thyrotoxic phase of postpartum thyroiditis
(59). In North America and Japan, however, TSH-R Abs have
been reported to occur in postpartum thyroiditis, particu-
larly in the thyrotoxic phase. In a study of 25 Japanese post-
partum women, TSH binding inhibitory Igs (TBII) were
present in six, and in five of these thyroid-stimulating anti-
body (TSAb) activity was high. This study showed, addi-
tionally, that the hypothyroid phase was associated with an
increased activity of TBII and/or a disappearance of TSAb
activity (69). In another Japanese study of 71 TPO antibody-
positive subjects in early pregnancy, 7 were also positive for
TSH-R Abs, and all 7 developed thyroid dysfunction in the
postpartum period. Five developed Graves’ disease, and the
remaining 2 developed transient hypothyroidism (70).
Interestingly, some case reports from North America have
described postpartum thyroiditis preceding the onset of
Graves’ disease (71, 72). On the basis of an extensive immu-
nological evaluation of two of these cases, Sarlis et al. (71)
have proposed a possible pathogenic association in which
TSH-R Abs play a role in the transient phases of thyrotox-
icosis and hypothyroidism in the postpartum period. The
authors demonstrated heterogeneity in TBII and showed
the presence of stimulating TSH-R Abs activating either the
cAMP or the phosphatidylinositol 4,5-bisphosphate signal
cascades at the time of diagnosis of postpartum Graves’
disease. It was therefore suggested that susceptible individ-
uals might develop an immunological response that can trig-
ger the appearance of a mixture of species of TSH-R Abs,
which may lead to the sequential occurrence of painless
thyroiditis and Graves’ disease after pregnancy. The multiple
phases of thyrotoxicosis and hypothyroidism that can occur
in these patients may then reflect the existence and changing
spectrum of the various TSH-R Abs in their sera (71). In our
area—The Netherlands—however, the prevalence of TSH-R
Abs is very low (0.3%), and until now—as in the United
Kingdom—cases of TBII-positive postpartum thyroiditis
have not been reported. We are thus of the opinion that in
Western Europe TSH-R Abs in the postpartum period should
be taken as reflecting de novo or relapsing Graves’ disease
(and not of postpartum destructive thyroiditis in the sense
we discuss it here).
Interestingly, several studies have found that the first post-
partum year not only constitutes an important risk factor for
the development of autoimmune destructive thyroiditis, but
also of Graves’ disease (73–76). With regard to persistent
thyrotoxicosis after pregnancy, Hayslip et al. (77) tested se-
rum for the presence of TSH-R Abs in three such cases, all of
which were positive for both TBII and TSAb. The authors also
tested 21 women with classical postpartum thyroiditis for
TSH-R Abs. Only one woman with hypothyroidism had high
levels of TSH-R Abs when she was hypothyroid and 1 month
after initiation of T4 therapy.
In conclusion, exacerbation of existing Graves’ disease or
de novo Graves’ disease does occur after pregnancy. How-
ever, studies differ in prevalence between North America
and Japan vs. Europe. It would be of interest to study the
onset of Graves’ disease in relation to the puerperal period
in larger prospective studies.
IV. Cell-Mediated Immunity, Autoimmune
Thyroiditis, and Postpartum Thyroiditis
T lymphocytes are crucial in the pathogenesis of autoim-
mune thyroiditis (6, 78–83). This has been clearly shown in
T lymphocyte transfer studies in animal models of sponta-
neously developing autoimmune thyroiditis (84), such as the
biobreeding-diabetes prone (BB-DP) rat (85), the obese strain
(OS) chicken, and the nonobese diabetic (NOD) mouse
(86–89).
First, autoreactive T lymphocytes must be involved in the
autoimmune process because the autoreactive B lympho-
cytes need the help of T-helper 2 (TH2) lymphocytes to
produce the TPO and Tg antibodies of the IgG isotype (90).
TH2 lymphocytes bear the marker CD4 and produce the B
cell-stimulatory cytokines IL-4 and IL-5 (91). Another TH2
type cytokine is IL-10, which has immunosuppressive capa-
bilities, particularly for cell-mediated immune destructive
mechanisms (92, 93). Hence TH2 lymphocytes are presently
considered as relatively harmless for target cells in endocrine
autoimmune diseases, also because the antibodies play only
a secondary role.
Apart from TH2 lymphocytes, there is a subset of T cells
that is also CD4, the so-called T-helper 1 (TH1) lympho-
cytes. These cells are—unlike TH2 cells—well equipped to
stimulate the cytotoxic and cytolytic arm of the cell-mediated
immune system, e.g., to activate macrophages and natural
killer (NK) cells via cytokines such as -interferon (IFN) to
kill target cells (94) (Fig. 2).
In addition to CD4 TH1 cells, T lymphocytes of CD8
phenotype are also generally involved in the destruction of
target cells (Fig. 2) (6). These cytotoxic cells recognize au-
toantigens directly on target cells when in the context of
major histocompatibility complex (MHC) class I molecules.
Target cells are killed by CD8 T lymphocytes via perforin
and other cytotoxic molecules.
The balance between life and death of target cells is also
regulated by proapoptotic and antiapoptotic factors opera-
tive in the target cells when under immune attack. Proapo-
ptotic signal generation by the death receptor CD95—also
known as Fas— requires recruitment and activation of down-
stream initiator and effector caspases (a family of cysteine
proteases that catalyze the enzymatic and catabolic reactions
that lead to cell death), which can be antagonized by anti-
apoptotic molecules such as members of the bcl-2 family and
cFLIP (95, 96).
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The interaction between CD95 and its ligand CD95L has
recently been proposed as a major mechanism for autoim-
mune thyrocyte destruction in Hashimoto’s thyroiditis (97,
98). CD95L is constitutively expressed on thyrocytes (99).
After autoimmune T and B cell inflammation, thyrocytes also
start to express CD95 in Hashimoto’s thyroiditis. The thy-
rocytes are therefore likely to die through “suicide” or “frat-
ricide” (100). Although CD8 T cells do occur in high num-
bers in Hashimoto’s thyroiditis, a direct cytotoxic effect of
CD8 infiltrating T lymphocytes is, however, less likely as
a major contributor to thyrocyte destruction: CD8 T cells
that approach thyrocytes are CD95 positive and are thereby
themselves vulnerable to apoptosis via the CD95L expres-
sion by thyrocytes (99). It is probably the secretion of TH1
cytokines by CD4 and CD8 T cells in Hashimoto’s thy-
roiditis that is important: IFN  activates infiltrating macro-
phages to become cytolytic/cytotoxic, while the cytokine
also promotes the caspase up-regulation and CD95-induced
apoptosis in thyrocytes of Hashimoto’s glands (6, 101). There
are indications that in Graves’ disease T cell infiltrates work
differently—although up-regulating CD95 on thyrocytes, the
T cells now also up-regulate antiapoptotic mechanisms
(cFLIP and Bcl-xl) in the thyrocytes due to their TH2 type
character. The final outcome is then nondestructive (102).
There are many studies on immune cell abnormalities in
postpartum thyroiditis. These will be reviewed below. Col-
lectively, these studies support the notion that such mech-
anisms play a role and that indeed the syndrome should—at
least in part—be regarded as belonging to the spectrum of
autoimmune thyroid diseases.
A. Histology of postpartum thyroiditis
The histological features of postpartum thyroiditis are en-
tirely consistent with an autoimmune etiology. Two types of
thyroidal lymphoid cell infiltrates are normally observed in
classical Hashimoto’s thyroiditis:
1. Destructive infiltrates (103). These infiltrates do not show a
recognizable pattern of topological organization and consist
of mixtures of CD4 and CD8 T lymphocytes, macro-
phages, NK cells, and some B lymphocytes. The infiltrating
cells are found in areas of destroyed thyrocytes, which are
CD95 and CD95L positive. The milieu of the infiltrates is
presumably of TH1 character, promoting its cytolytic poten-
tial (91).
2. Focal accumulations of lymphoid cells with a high degree of
histological organization (104). These infiltrates are not de-
structive and may be found side-by-side intact thyrocytes in
mild forms of Hashimoto’s autoimmune thyroiditis (focal
thyroiditis). They can also be seen in Graves’ disease (105–
107). The infiltrates represent intrathyroidally developed
lymphoid tissue of an architecture similar to that of mucosa-
associated lymphoid tissue. Such thyroid-associated lym-
phoid tissue is composed of T cell zones, B cell follicles, and
plasma cells in the periphery of the focal infiltrate. Some-
times the plasma cells extend in cord-like structures radiating
from the lymphoid tissue between the thyroid follicles. We
presume that this lymphoid tissue is involved in the gener-
ation of the actual thyroid autoimmune reaction, including
the production of autoantibodies (108). The T cell zones of the
intrathyroidal lymphoid tissue consist of CD4 and CD8
lymphocytes in a ratio of about 2–3:1. The function of the T
lymphocytes in these focal accumulations is thought to be the
regulation of the autoimmune response. In Graves’ disease,
such infiltrates presumably have a TH2 pattern of cytokine
production that might confer a defense against apoptotic
destruction.
With regard to postpartum thyroiditis, Mizukami et al.
(109) described histological and immunohistochemical find-
ings of thyroid tissue in a series of 15 patients with this
disease. Histology revealed both the focal organized and the
diffuse destructive type of lymphocytic thyroiditis with fol-
liculolysis and disruption. Intact follicles showed mild epi-
thelial hyperplasia. There was no difference between the
hypothyroid and early recovery phase. Three specimens
from the late recovery phase showed only histological fea-
tures of focal thyroiditis without follicular destruction. Un-
fortunately, there are no histological data on patients with
permanent hypothyroidism after an episode of postpartum
thyroiditis. The immunohistochemical examination by Mi-
zukami et al. (Ref. 109, but see Ref. 110) as well also showed
a significantly increased expression of MHC class II antigen
on thyroid follicular cells. Since inflammatory T cell cyto-
kines, such as IFN, up-regulate MHC class II expression on
thyrocytes, such expression probably indicates a local pro-
duction of such cytokines by infiltrating T cells (111, 112). The
importance of MHC class II expression on thyroid epithelial
cells is no longer viewed as a sign of the thyrocytes’ capability
to present antigen to T cells. Although capable of stimulating
T cells, other professional antigen-presenting cells in their
vicinity, such as the dendritic cells, are better in such func-
tion. The MHC class II expression of the thyrocytes is therefore
just a sign of the TH1 pattern of cytokine production in their
vicinity, which will actually contribute to their destruction.
B. T lymphocytes
Chan and Walfish (113) studied the expression of MHC
class II as a marker of T lymphocyte activation. Of 28 post-
partum patients, 4 were studied in the thyrotoxic phase and
11 in the hypothyroid phase, and the remaining 13 were
euthyroid after a previously documented hypothyroid or
thyrotoxic phase. Patients in the thyrotoxic phase had a sig-
nificantly increased proportion of circulating activated T
lymphocytes. Similar data were not provided for patients in
the hypo- and euthyroid phases. When CD4 and CD8 subsets
were quantified, patients in the hypo- and euthyroid states
had significantly higher percentages of the CD4 subset and
significantly lower percentages of the CD8 subset, leading
to higher CD4/CD8 ratios compared with thyrotoxic
patients.
Stagnaro-Green et al. prospectively followed 33 thyroid
autoantibody-positive and 28 antibody-negative women
during pregnancy and 6 months postpartum. Evidence of T
cell activation (i.e., raised numbers of MHC-class II cells)
was found in the postpartum period, and a higher CD4/CD8
ratio occurred in women developing postpartum thyroiditis
compared with normal postpartum TPO antibody-negative
controls (34).
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In a prospective study of 291 women, 15 of whom devel-
oped postpartum thyroiditis, Kuijpens et al. studied various
cell-mediated immune parameters including the number of
circulating MHC-II T lymphocytes in pregnant women
from 12 wk of gestation until 9 months postpartum. They too
detected T cell activation in TPO-positive women subse-
quently developing postpartum thyroiditis: percentages of
MHC-II T cells were significantly higher at all time points
studied (12 and 32 wk of gestation and 4 wk postpartum) in
TPO-positive women developing postpartum thyroiditis
compared with TPO-positive women not developing the dis-
ease (26) (Fig. 3).
Collectively, the data from these studies are suggestive of
an activation of circulating T cells in postpartum thyroiditis.
Jansson et al. (114) investigated circulating, as well as in-
trathyroidal, lymphocyte subsets in different stages of post-
partum thyroiditis. The authors were unable to find differ-
ences in circulating lymphocyte subsets between 9 thyrotoxic
and 18 hypothyroid patients vs. normal controls. Intrathy-
roidal lymphocyte subsets obtained by fine-needle aspiration
were comparable in the 10 hypothyroid and the 3 thyrotoxic
patients with adequate aspirates (in normal subjects, intra-
thyroidal lymphocytes are absent). The authors found dif-
ferences between subset distribution in the thyroid and the
circulation. There was a relative accumulation of B cells
within the thyroid of hypothyroid patients compared with
peripheral blood. Also, a relative decrease in intrathyroidal
CD8 T cells resulted in higher CD4/CD8 ratios in the
thyroid aspirates than in the blood of hypothyroid patients
with postpartum thyroiditis. According to the authors, these
data are compatible with the local synthesis of thyroid-
directed autoantibodies in postpartum thyroiditis (114).
However, in our opinion these data just highlight the dif-
ferent migration and homing patterns of the various subsets
of immune cells to sites of chronic inflammation.
C. Natural killer (NK) cells
Apart from the CD3 T cells and the CD19 CD20 B
cells, there is yet another subset of lymphocytes important in
cell-mediated immunity. These are the NK cells or large
granular lymphocytes. NK cells are lymphocytes with dis-
tinct morphological and functional properties. Their cell sur-
face classically expresses CD16 and CD56 antigens. NK cells
are able to kill tumor cells without the need for prior sen-
sitization. NK cells are activated by IL-2, IFN, and - and
particularly by IL-12. The cells have two main mechanisms
of target cell killing.
The first mechanism is ADCC. Fc receptor-bearing cells,
such as the NK cells and macrophages, are capable of binding
to the thyrocyte via a linking of their Fc receptors with
antibodies bound to the surface of thyrocytes. Once acti-
vated, the NK cells lyse target cells via the release of perforin
and lymphotoxin (6, 115, 116).
The second mechanism makes use of cell-cell contact in
which special, yet ill defined, lectin-like NK-receptors,
known as NKR-P1 receptors, recognize glycosylated surface
molecules on target cells. Once activated, the NK cells lyse
target cells again via the release of perphorin and lympho-
toxin. NK cells are also able to secrete cytokines such as IFN,
FIG. 3. The percentage of circulating
activated T cells in TPO-antibody pos-
itive (TPO-Ab) pregnant women. The
percentage of circulating T cells was
calculated for each pregnant woman as
the mean of three values measured at
gestational weeks 12 and 36 and 4 wk
postpartum. As can be seen, TPO-Ab
women who develop postpartum thy-
roiditis (PPTD, n  10) have signifi-
cantly higher values of circulating ac-
tivated T cells than TPO-Ab women
who do not develop PPTD (n 16). The
difference is statistically significant (t
test, P  0.05, Instat program). The
hatched area represents values found in
nonpregnant, TPO-Ab, healthy con-
trols. [Reproduced with permission
from J. L. Kuijpens et al.: J Clin Endo-
crinol Metab 83:1959–1966, 1998 (26).
© The Endocrine Society.].
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which further promotes the cellular immune response and
recruits T cells. Interestingly, NK cells (but also the CD8
cytotoxic T lymphocytes) possess, in addition to the above
described receptors that activate the killing machinery in the
cell, special inhibitory receptors. These so-called killer cell
inhibitory receptors (KIRs) are able to recognize MHC class
I molecules. Hence, when target cells abundantly express
MHC-class I molecules, NK cells will not be able to kill these
cells (116).
Neither Hayslip et al. (77) nor Hidaka et al. (117) observed
a difference in functional NK activity of peripheral blood
lymphocytes in patients with postpartum thyroiditis com-
pared with normal postpartum women. However, when
Hidaka et al. (117) analyzed serial changes of NK cell activity
in individual patients they found a significant increase in NK
activity during the postpartum phase of thyrotoxicosis
caused by either destructive thyroiditis or Graves thyrotox-
icosis (around 2–4 months postpartum). This might suggest
that thyrotoxicosis per se stimulates NK cell activity. Indeed,
IL-12—a NK activating cytokine—is raised in the thyrotoxic
state (118).
We, ourselves, should also realize that NK cells are not
only involved in target cell lysis, but also act in the regulation
of the B and T cell growth and activation (119). Changes in
NK cell numbers and activities may therefore not only serve
defense mechanisms directly, but may also reflect altered
setpoints in the immune system. This latter notion may ex-
plain observations by Kuijpens et al. (26). These investigators
found that NK cell levels were not associated with postpar-
tum thyroiditis itself, but with TPO antibody positivity: TPO
antibody-positive pregnant women had low percentages of
circulating NK cells. There was no difference between those
developing postpartum thyroiditis and those who did not.
Interestingly, NK cell numbers are also low in states of psy-
chological depression and may therefore reflect altered set-
points in the hypothalamo-pituitary-adrenal axis, which oc-
curs in severely depressed patients.
In conclusion, changes in NK cell numbers and activities
have been found in postpartum thyroiditis, but the role of
NK cells in the development of postpartum thyroiditis re-
mains uncertain. Clearly, further research is needed.
When the above described data on TPO antibodies, com-
plement, activated T cells, apoptosis, and the histology of
postpartum thyroiditis are combined, a picture is emerging
that at least part of the postpartum thyroiditis cases must be
regarded as aggravations of an ongoing process of thyroid
autosensitization, leading to an enhanced violation of thy-
rocyte integrity. When their cases of postpartum thyroiditis
are studied in detail, it is relevant to note that Kuijpens et al.
(26) came to the conclusion that two forms of postpartum
thyroiditis might exist, an autoimmune and a nonautoim-
mune form. The autoimmune form, 10 of their relatively low
number of 15 cases, was immunologically characterized by
the presence of TPO antibodies and various cell-mediated
immune disturbances. The nonautoimmune form, 5 cases,
lacked any sign of immune involvement. These latter cases
were also different in their symptomatology in that they
experienced only a mild transient phase of thyrotoxicosis.
Further research on larger series of postpartum thyroiditis
cases is necessary to confirm or refute the existence of two
such forms and their associated clinical implications.
In postpartum thyroiditis the rapid destruction of thyroid
follicles is most frequently followed by a recovery of thyroid
function. At present, it is largely unclear how the immune
system generally regains equilibrium after activation; and
this is also the case for the recovery phase after postpartum
thyroiditis. A few mechanisms have been discussed in this
respect (74). First, apoptosis of T cells can be induced by
exposure to large amounts of antigen. The transience in post-
partum thyroiditis might thus be due to the induction of
clonal apoptosis of thyroid-specific T cells that may follow
the release of thyroid antigens in the circulation when many
thyrocytes lose their integrity. Second, it is now known that
cells traffic between fetus and mother during normal human
pregnancy (120), and particularly the delivery is a time for
major entry of fetal cells into the mother’s circulation (121).
It has therefore been hypothesized that if tolerance to these
microchimeric cells develops, immuno-tolerogenic mecha-
nisms similar to those observed during pregnancy are in-
volved, and that this may lead to an attenuation of the thy-
roid autosensitization (74, 122). Indeed, in a mouse model it
has recently been shown that in 60% of pregnant animals
with experimentally induced thyroiditis fetal cells were
present within the maternal thyroid, as compared with no
fetal cells in the thyroids of the control mice (123, 124). Also
the induction of PRL secretion as a result of breast-feeding
is a factor that could play a role in the transient character of
postpartum thyroiditis. PRL is able to influence immune
function (125). Human T and B lymphocytes contain PRL
receptors, the immuno-incompetent state in hypophysecto-
mized mice is restored by PRL administration, and antibod-
ies to PRL can inhibit lymphocyte proliferation (126–128).
The effects of hyperprolactinemia on human immune func-
tion have, however, not been clearly elucidated. With respect
to breast-feeding and the occurrence of postpartum thyroid-
itis, it should be noted that in a prospective study no relation
between breast-feeding and postpartum thyroiditis was
noted (21).
V. The Pathogenesis of Autoimmune Thyroiditis:
A Polygenic, Multifactorial Disease. Are Multiple
Factors Also Involved in the Outbreak of
Postpartum Thyroiditis?
Since the above reviewed data are highly suggestive that
the puerperal period is a precipitating factor for an aggra-
vation of autoimmune thyroiditis, it becomes relevant to
address the question on the pathogenesis of autoimmune
thyroiditis in general. The natural course of autoimmune
thyroiditis is thought to encompass a long subclinical pro-
dromal phase. Therefore, researchers have turned to the ear-
lier mentioned inbred animal models of spontaneously oc-
curring variants of autoimmune thyroiditis to study the
pathogenesis and the early phases of the disease. The studies
performed in animal models have led to the conclusion that
organ-specific autoimmune syndromes, such as autoim-
mune thyroiditis, should be regarded as polygenic diseases,
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with a penetrance that is strongly influenced by environ-
mental factors (Fig. 4) (6, 87). The interaction of various
permissive environmental factors with an immune system
that fails to distinguish adequately between self and nonself
leads to the activation of a plethora of pathogenic immune
mechanisms. In the animal models an afferent stage of en-
hanced autoantigen presentation, a central stage with exces-
sive expansion and maturation of autoreactive T and B lym-
phocytes, and an efferent stage of the pathogenic effects of
autoreactive T lymphocytes and B lymphocytes on their tar-
gets can be discerned (Fig. 4). In each stage, endogenous
and/or exogenous factors are able to elicit the abnormalities
characteristic of that stage (Fig. 4). Only combinations of
genetic susceptibilities, gender, and environmental factors,
such as infectious agents, dietary factors, and toxins, lead to
clinically overt autoimmune disease.
Also in humans there is evidence that the clinically overt
stage of autoimmune thyroiditis is preceded by a phase of
TPO antibody-positive subclinical thyroiditis of variable du-
ration (Fig. 5). Genetic factors are not the only determinants
in the development and progression of the disease. This is
elegantly illustrated by studies of chronic autoimmune hy-
pothyroidism in twins (129). Genetic susceptibility is impli-
cated in autoimmune thyroid disorders by concordance rates
that are higher in monozygotic pairs than in dizygotic pairs.
However, the fact that the concordance rate among monozy-
gotic twins is always below 1 strongly suggests that envi-
ronmental factors also are of etiological importance.
FIG. 4. In a bird’s eye view, the following
developmental stages can be distin-
guished in the thyroid autosensitization
process, leading to spontaneously devel-
oping thyroid autoimmune disease in an-
imal models: 1. An initial, afferent phase
of an accumulation of antigen presenting
cells (APC), particularly of dendritic cells
and subclasses of macrophages (M) in
the thyrocyte (T). Such APC influx can be
induced, for instance, by an aspecific ne-
crosis of thyrocytes due to iodine intoxi-
cation. 2. A later, central phase of an ap-
parently uncontrolled production of
autoreactive CD4T lymphocytes, CD8
T lymphocytes, and of autoantibodies of
the IgG class. Initially, this production of
immune effectors takes place in the
draining lymph nodes due to the traffic of
APC from the thyroid to the draining
lymph nodes. Later, immune effectors
are also produced in areas of lymphoid
tissue locally developed in the thyroid.
The uncontrolled production of immune
effectors is due to an inborn aberrant reg-
ulation of the immune response. Many
defects leading to such aberrant regula-
tion exist in the various animal models.
Some are listed in the figure. 3. A last,
efferent phase in which the thyrocytes be-
come susceptible for the autoimmune at-
tack exerted by the generated autoreac-
tive T lymphocytes, the macrophages and
the autoantibodies (see also Fig. 2). This
commonly results in the destruction of
the tissue, or in a blockade of its function
or growth, as is the case in autoimmune
hypothyroidism. Occasionally, it may
also result in stimulation of the thyro-
cyte, as is the case in Graves’ disease (see
also Fig. 2). Aabs, Autoantibodies; Cy, cy-
tokines; en, endothelial cell; mo, mono-
cyte; P, plasma cell; Tr, T regulator cell.
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A. Genetic influences
Multiple genes determine the aberrant immune response
toward self in organ-specific autoimmunity. Most important
are the genes of the major histocompatibility region (MHC)
region located on the short arm of chromosome 6. MHC
molecules are the antigen-presenting molecules located on
the cell membrane of antigen-presenting cells (130). These
molecules determine the T cell response to specific peptide
structures (Fig. 6) (87). There is a strong association between
the genetic inheritance of the MHC molecules HLA-DR3,
-DR-4, and -DR-5 and the occurrence of thyroid-specific au-
toimmune diseases (131). It is thought that these MHC mol-
ecules and the associated DQ molecules represent structures
with an enhanced capability to present the major thyroid
antigens TPO and Tg to T cells (57).
Genes other than the MHC genes are also involved in the
aberrant immune response toward self. One of these genes,
the cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene on
chromosome 2q33, is a general regulator of the immune
reaction (132). CTLA-4 is a costimulatory molecule with an
important negative effect on T cell activation (Fig. 6) (133).
The CTLA-4 locus has recently been linked to and associated
with the occurrence of Graves’ disease and thyroid-associ-
ated orbitopathy as well as with the occurrence of type I
diabetes (134–137).
With regard to postpartum thyroiditis, several authors
have reported an association between the syndrome and
HLA-DR3 (34, 138–140), HLA-DR 4 (5, 141, 142), and HLA-
DR5 (35, 61, 139, 143) (Table 2). Jansson et al. (5) found that
all three women who developed permanent hypothyroidism
were HLA-DR5 positive, suggesting that this phenotype
might be related to the development of permanent hypo-
thyroidism. In a population-based case-control study in the
United Kingdom including 122 women (of whom 58 had
TPO and/or Tg antibodies and 64 had postpartum thyroid-
itis) and 161 thyroid autoantibody-negative controls, no sig-
nificant association was found between the CTLA-4 poly-
morphism and postpartum thyroiditis (144).
In conclusion, there are clear associations of certain MHC
genes with postpartum thyroiditis.
B. Female gender, pregnancy, and thyroid autoimmune
predisposition
Thyroid autoimmune diseases have a predilection for the
female gender (145, 146). The female-male ratio for most
thyroid diseases is 4:1 (147, 148). Likewise, in the NOD
mouse model, females are more prone to autoimmune dis-
eases. Castration of young males increases the prevalence
rates of type I diabetes mellitus at a later age, indicating a
protective role of T. Indeed, when the male castrated NOD
mice are treated with T, autoantibody levels and autoim-
mune inflammation decrease again (149, 150). However, cas-
tration of young female NOD mice does not lead to a sig-
nificant lowering of autoimmune insulitis; neither does
treatment with supraphysiological doses of E of NOD mice
lead to an acceleration of autoimmunity (150). In other an-
imal models of autoimmune disease (systemic lupus ery-
thematosus models) E administration does have some ac-
celerating effects (151). This might indicate that the role of
female hormones is limited in endocrine autoimmune dis-
eases. In human male-to-female transsexuals castration fol-
lowed by treatment with female hormones did not induce
higher levels of TPO antibodies compared with the normal
female population (152). This illustrates the complexity of the
phenomenon of T-induced immunosuppression and high-
lights the danger of extrapolating from animal data to the
human situation.
During pregnancy many patients with autoimmune dis-
orders experience a remission (148, 153–156). The explana-
tion for this phenomenon is based on a heightened state of
immune tolerance induced by the pregnant state (157, 158).
Adaptation of the maternal immune system is essential for
immune tolerance of the fetus, since the fetus expresses pa-
ternal MHC molecules (157, 158).
The placental immune system plays a central role in the
FIG. 5. A scheme depicting the gradual
loss of thyroid reserve over time (often
years) due to thyroid autoimmune mech-
anisms. On the basis of a genetic predis-
position for endocrine and thyroid auto-
reactivity, an insult on the level of the
thyroid [leading to the attraction of anti-
gen-presenting cells (APC)], and various
other eliciting factors (e.g., smoking) (see
Fig. 4) a thyroid autoimmune reaction is
initiated. TPO antibodies are markers of
the ongoing thyroid autosensitization
process. Pregnancy ameliorates the pro-
cess, while the puerperal period aggra-
vates thyroid autoimmunity. If thyroid
reserve was already considerably com-
promised before pregnancy, or if the tran-
sient autoimmune attack in the puer-
peral period is severe enough, subclinical
hypothyroidism and even overt hypothy-
roidism will develop (PPTD).
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acceptance of the fetus (159–161). In early and successful
pregnancies nonclassical NK cells (with a distinctive phe-
notype: CD56 CD16 CD3) and macrophages accumu-
late in the decidua at the feto-maternal interface. These cells
exert only a low cytolytic activity on the fetal trophoblastic
cells and play a primary role in placental morphogenic pro-
cesses and down-regulate the local immune response (162).
The functions of these local immune cells are governed by
various mechanisms, such as the expression on the tropho-
blastic cells of a special paternally imprinted MHC-class I
molecule, i.e., HLA-G, and also by the local production of
various pregnancy-associated proteins and hormones (93,
121, 163). These proteins and hormones include the enzyme
indolamine 2,3 dioxygenase involved in tryptophan metab-
olism (164, 165), a pregnancy-specific glycoprotein encoded
by the gene PSG11 and the hormones progesterone, E2, and
human CG (hCG). These later hormones have, in addition to
their local placental effects, systemic effects (163, 166). Par-
ticularly progesterone is an important contributor to preg-
nancy-associated immunomodulation (167). Immunological
effects of progesterone are partly mediated by a protein
fraction of 34 kDa: the so-called progesterone-induced block-
ing factor (PIBF) (168, 169). This factor is produced by pro-
gesterone-exposed activated T cells and affects both placen-
tal NK cells and macrophages, but also the circulating cells
(168–170). PIBF is endowed with immunomodulatory prop-
erties such as a strong regulating activity on perforin ex-
pression by NK cells (158, 169, 171). It also affects the TH1/
TH2 balance via an increased production of IL-3, IL-4, and
IL-10 and a decreased production of IL-12 from lymphocytes
and macrophages (158). Treatment with anti-PIBF induces a
shift toward a TH1 response (decreased IL-10 and increased
IFN production) and leads to increased rates of pregnancy
resorption (172).
E2 has a similar effect on the TH1/TH2 balance (163). In
neuroantigen-specific T cell clones, E2 showed a dose-
dependent enhancement of antigen-stimulated IL-10 secre-
tion. The secretion of IFN was also enhanced but the max-
imum enhancement occurred at lower E2 concentrations
and at lower magnitudes than observed for IL-10 (173).
Interestingly, progesterone induces hCG release from the
trophoblast through its stimulation of TH2-type cytokines
(158, 166, 170). hCG subsequently stimulates progesterone
production from the corpus luteum (166), thus creating a
positive feedback loop.
In conclusion, various factors, but particularly hormonal
factors, down-regulate TH1-mediated effector arms of the
immune system during pregnancy.
A rebound reaction to the above described pregnancy-
associated immunomodulations is thought to induce the ag-
gravation of thyroid autoimmune syndromes in the puer-
peral period. If, indeed, autoimmune thyroid failure is
induced by TH1 mechanisms while TPO antibodies are sec-
ondary to thyroid destruction, a TH2 to TH1 “return shift”
in the puerperium might explain the outbreak of postpartum
thyroiditis. However, considering the shift from TH1 to TH2
immune response during pregnancy, the amelioration of
Graves’ disease frequently observed during pregnancy re-
mains puzzling, since this disease is considered to be a typ-
ical TH2-type disease. Apparently, immunomodulating
mechanisms other than TH1/TH2 shifts also play a role in
pregnancy.
Interestingly, and from a clinical point of view, important,
the fall in TPO antibodies during pregnancy is not associated
with an improvement of thyroid function. In a prospective
study of 87 thyroid antibody-positive women with normal
thyroid function at the time of initial screening, Glinoer et al.
(174) found that despite the expected decrease in the titers
of thyroid antibodies during gestation, thyroid function
showed a gradual deterioration toward subclinical hypothy-
roidism. This is due to the fact that pregnancy in itself, in
addition to the above described immunological phenomena,
affects thyroid function directly since there is an increased
demand for thyroid hormones. Three independent factors
concur to exert stimulatory effects on the thyroid machinery
to fulfill this increased demand. The first factor is the thy-
roidal response in the first trimester to adjust to the marked
FIG. 6. The interactions between antigen presenting cells (APC, in-
cluding virus-infected cells) and T cells at the level of antigen-specific
interactions, adhesion molecules, and costimulatory molecules. Pan-
els A and B represent interactions between MHC molecules, the T cell
receptor (TCR), and CD4/CD8 molecules. Panel C depicts interactions
between MHC and the TCR and between various adhesion molecules
(ICAM-1/LFA1, LFA-3/LFA-2) providing signal 1 for T cell stimula-
tion. Further interactions of the costimulatory molecules (CD80/
CD86 and CD28), provide a second signal essential for full T cell
activation. In such full T cell activation (signal 1 plus signal 2) CTLA-4
is up-regulated on the T cell. The interaction of CTLA-4 with CD80/
CD86 on the antigen-presenting cells (APC) provides negative signals
for the activated T cell to down-regulate the initiated response. In-
terestingly, patients with endocrine autoimmunity have a polymor-
phism of the CTLA-4 molecule. [Adapted with permission from A.
Hoek et al.: Endocr Rev 18:107–134, 1997 (87). © The Endocrine
Society.].
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increase in the circulating levels of T4 binding globulin, the
latter due to increased E production from the placenta. The
second factor is related to the thyrotropic action of hCG, also
occurring in the first trimester. The third factor, operative
later in gestation, is related to modifications in the peripheral
metabolism of thyroid hormones, particularly at the placen-
tal level (175, 176).
C. Environmental factors, iodine intake
Both iodine excess and iodine deficiency are capable of
disturbing an existing tolerance for thyroid autoantigens.
Most important in this respect is an iodine excess in auto-
immune-prone individuals (177–179). After the introduction
of iodine supplementation to a population, a rise in thyroid
autoantibodies and a higher incidence of lymphocytic thy-
roiditis has been observed (180–184). In goitrous NOD mice,
OS-chickens, or BB-DP rats, a high iodine intake induces a
rise in the titer of thyroid autoantibodies and an outburst or
acceleration of lymphocytic thyroiditis in these animals
(185–187).
Proposed pathogenic mechanisms of this iodine-induced
thyroid autoimmunity are: 1) an iodine-induced thyrocyte
necrosis with an increased release of autoantigens resulting
in an enhanced attraction of antigen-presenting cells (188,
189); 2) a higher antigenicity of Tg due to a higher iodination
grade (190–192); and 3) a direct stimulation of B lympho-
cytes, T lymphocytes, dendritic cells and macrophages by
iodine or iodinated substances.
The prevalence of postpartum thyroiditis does not seem to
be related to the iodine intake status of a population (Table
1). Interestingly, in this respect, in a case-control study, Oth-
man et al. (193) did not observe a difference in iodine excre-
tion in the immediate postpartum period between 73 women
who developed postpartum thyroiditis and those 135 women
who did not. With regard to the effect of changes in iodine
intake on the occurrence of postpartum thyroiditis, the data
are conflicting. On the one hand, there are data indicating
that increased iodine intake can influence the severity of
thyroid dysfunction in postpartum thyroiditis. In Sweden, an
iodine-sufficient area, Ka¨mpe et al. treated 20 women who
were TPO positive in early pregnancy with iodine (0.15
mg/d) for 40 wk postpartum. In those women who devel-
oped thyroid dysfunction, TSH levels were higher and T4
levels were lower compared with the group who received no
medication (194). On the other hand, Nøhr et al. (195) in
Denmark, in an area with mild to moderate iodine insuffi-
ciency, performed a placebo-controlled, randomized, dou-
ble-blind trial on the impact of iodine supplementation (0.15
mg/d) during pregnancy and the postpartum period in 72
TPO antibody-positive women. In this study, iodine supple-
mentation did not induce or worsen postpartum thyroiditis
(184).
D. Environmental factors, toxins, and cigarette smoking
Chemical toxins constitute another source of potential
pathogenic factors in the development of thyroid autoim-
munity (196). Exposure to methylcholanthrene enhances the
thyroid autoimmune response in Buffalo rats (177).
In humans, thiocyanate from tobacco smoke is probably
the most important environmental toxic factor in the devel-
opment of Graves’ disease. Thiocyanate is actively metabo-
lized by the thyroid and is able to inhibit iodine transport. It
is also a competitive substrate for TPO (197–202). It is there-
fore not surprising that it has been hypothesized that the
toxic effects of thiocyanate explain why smoking leads to
thyrocyte necrosis and/or thyroid metabolic abnormalities,
processes that are driving forces behind a thyroid-specific
autoimmunization (203).
Alternatively, smoking might have direct effects on the
immune system. Smoking leads to clear alterations in the
function of pulmonary monocyte-derived cells and to an
altered production of proinflammatory cytokines in the lung.
Whether this is reflected in functional aberrations of systemic
or intrathyroidal monocytes and other antigen-presenting
cells needs to be investigated.
In the United Kingdom, almost two-thirds of patients with
Graves’ ophthalmopathy smoke cigarettes in contrast to 10–
20% of the normal healthy population (204, 205). In a recent
population-based twin case-control study, clinically overt
autoimmune thyroid disease was significantly associated
with smoking. Most importantly, this association remained
significant in disease-discordant monozygotic twin pairs,
eliminating the effect of genetic factors in the development
of thyroid disease (206).
With regard to postpartum thyroiditis, a case-control
study in the United Kingdom showed that smoking more
than 20 cigarettes/d was significantly related to the devel-
opment of the syndrome (21) but not with the development
of permanent autoimmune hypothyroidism (207). In a pro-
spective study of 291 women, of whom 15 developed post-
TABLE 2. Association between HLA class II expression and postpartum thyroiditis
First author (reference) Yr
Ethnic origin
Association
Postpartum thyroiditis (n) Controls (n)
Farid (139) 1983 Caucasian (25) Caucasian (17) DR3, DR5
Lervang (141) 1984 Caucasian (13) Caucasian (704) DR4
Jansson (5) 1985 Caucasian (50) Caucasian (243) DR4
Thompson (142) 1985 DNS (32) DNS (100) DR4
Tachi (140) 1988 Japanese (44) Japanesea DR3
Vargas (35) 1988 Caucasian (38) Caucasian (98) DR5
Kologlu (138) 1990 Caucasian (221) Caucasian (600) DR3
Stagnaro-Green (34) 1992 Caucasian (11) Caucasian/Hispanic (42) DR3
Parkes (143) 1996 Caucasian (86) Caucasian (1010) DR5
DNS, Data not shown.
a Historical controls.
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partum thyroiditis, Kuijpens et al. (208) found by multivar-
iate analysis that “ever smoked” was an independent risk
factor for postpartum thyroiditis with a relative risk of 3.1,
compared with “never smoked.”
In conclusion, evidence is growing that smoking is a clear
precipitating factor for autoimmune thyroid disease, includ-
ing the outbreak of postpartum thyroiditis.
VI. Postpartum Thyroiditis Viewed as a Transient
Exacerbation of a Preexisting and Ongoing Process
of Autoimmune Thyroiditis
The natural course of thyroid autoimmune diseases often
encompasses a long subclinical prodromal phase, and the
process of thyroid autosensitization and subsequent destruc-
tion of thyrocytes may fluctuate over several years. The ul-
timate failure of the gland in many cases is the consequence
of a process that started years earlier (Fig. 5). From this
perspective, postpartum thyroiditis is “just” an aggravation
of an existing autoimmune thyroiditis after an amelioration
of the inflammation during pregnancy (see above). The fluc-
tuations in intensity are driven by the hormonal changes
associated with pregnancy and the subsequent puerperal
period, and eliciting environmental factors. This is clearly
illustrated by the pattern of the TPO antibody titer during
pregnancy and the postpartum period (Fig. 5).
Figure 1 summarizes the reports on the TPO antibody
status in women with postpartum thyroiditis. Collectively,
these reports show that 30–60% of women positive for TPO
antibodies in pregnancy develop postpartum thyroiditis. Af-
ter a first episode of postpartum thyroiditis, the chance of
recurrence after a subsequent pregnancy is 70% in women
who are TPO antibody positive. The chance of postpartum
thyroiditis is 25% in TPO antibody-positive women without
a history of previous thyroid dysfunction in the puerperal
period (209).
VII. The Clinical Course of a Postpartum
Exacerbation of Autoimmune Thyroiditis
Postpartum thyroiditis classically runs a biphasic course:
a thyrotoxic phase is followed by a hypothyroid phase (1, 11,
34, 210). The disease can also present as either transient
thyrotoxicosis or hypothyroidism. Hypothyroidism tends to
occur earlier when preceded by thyrotoxicosis than when
occurring alone (21). The onset of thyrotoxicosis is variable,
ranging from the first to the sixth month postpartum and
lasting 1 to 2 months (12, 20, 21, 23, 24, 27, 29, 30, 33, 36). Five
authors have systematically investigated the symptoms of
postpartum thyroiditis compared with euthyroid postpar-
tum women (Table 3) (12, 23, 25, 36, 211). During the thy-
rotoxic phase the physical symptoms are usually mild com-
pared with Graves’ thyrotoxicosis, and fatigue, palpitations,
weight loss, heat intolerance, and irritability were more prev-
alent in women with postpartum thyroiditis than in euthy-
roid postpartum women. Other reported symptoms are psy-
chological disturbances (12, 22–24, 27, 30, 209, 212), tremor,
and nervousness (12, 20, 24, 27, 29, 209, 213). The thyrotoxic
phase of postpartum thyroiditis is due to leakage of thyroid
hormones from destroyed thyrocytes and is therefore
self-limiting.
The hypothyroid phase, developing approximately 4–8
months postpartum and usually lasting 4–6 months, is clin-
ically more important (see below). The hypothyroid phase of
postpartum thyroiditis is due to loss of thyrocytes by im-
mune destructive mechanisms. Prevalent symptoms are
muscle and joint aches and stiffness (23, 27, 29). In systematic
studies, these symptoms were not discriminatory in contrast
to fatigue, loss of concentration, and constipation (Table 3).
It is generally believed that mental depression is the most
prominent discriminatory symptom of the hypothyroid
phase of postpartum thyroiditis, often ascribed to the
changes consequent upon delivery and the lack of night rest
(12, 21, 23, 24, 27, 29, 32, 33, 36). Several studies have spe-
cifically, and solely, investigated the association between
postpartum thyroiditis and postpartum depression. A crit-
ical appraisal of the literature revealed that postpartum de-
pression is significantly associated with postpartum thyroid
dysfunction regardless of the thyrotoxic or hypothyroid
phase (22, 212). Consequently, in terms of clinical manage-
ment and appropriate treatment, it is pivotal to recognize the
origin of the depressive symptoms.
Harris et al. (214) examined the rates at which depression
occurred at 6–8 wk postpartum in 65 thyroid antibody (Tg
and TPO)-positive and 82 antibody-negative women.
Women with postpartum thyroiditis had a small but signif-
TABLE 3. Systematic studies on the symptomatology of postpartum thyroiditis
First author
(reference) Yr Country
No. included/no.
analysis of
symptoms
Time of
inclusion/time of
last assessment
Hypothyroidism Thyrotoxicosis
Depres-
sion
Fatigue/
concentration
loss
Consti-
pation
Fati-
gue
Palpita-
tions
Weight
loss
Heat
intolerance
Irrita-
bility
Amino (12) 1982 Japan 63/63a 3 mo pp/6 mo pp – –
Hayslip (23) 1988 USA 63/63 2nd day pp/6 mo pp –c –
Walfish (36) 1992 Canada 1,376/208 Delivery/12 mo pp – –
Lazarus (211) 1996 UK 152b/152 1 mo pp/9 mo pp – –
Kent (25) 1999 Australia 748/130 6 mo pp/6 mo pp – –
a Only thyrotoxic patients.
b Source population consisted of 1,996 women attending an antenatal clinic; inclusion thyroid antibody; 235 were thyroid antibody of these
152 were included.
c A dash denotes that the symptom is significantly more prevalent in women with postpartum thyroiditis than in normal euthyroid
postpartum women.
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icant excess of DSM III defined major depression (Table 4).
Pop et al. (212) studied 293 women from 32 wk of gestation
until 34 wk postpartum and also found an association of
major and minor depression (according to Research Diag-
nostic Criteria) with postpartum thyroiditis. Kent et al. (25)
also found that postpartum thyroiditis carries a slightly in-
creased risk for the occurrence of depression. However, in a
recent study from Spain in which 605 women were followed
Lucas et al. (28) found no association of depression with
postpartum thyroiditis. A different sociological background
in Spain compared with the countries in which the other
studies were performed might explain this negative result.
The presence of TPO antibodies per se is not associated with
postpartum depression (22, 25, 30).
After critically reviewing the present data, we conclude
that there is an association between postpartum thyroid dys-
function and depression. Considering the mechanism behind
this association, it is noteworthy that hypothyroidism influ-
ences neurotransmitters important in affective disorders; hy-
pothyroidism, for instance, reduces central 5-hydroxytryp-
tamine neurotransmission (215). This reduction reverses
with T4 replacement (216). Alternatively, it has been specu-
lated that cytokines released during a thyroid autoimmune
reaction, e.g., IL-1 and IL-6, interact with central neurotrans-
mission, initiating depression (4).
Whether goiter is a symptom of postpartum thyroiditis is
still questionable. In most clinical studies of postpartum thy-
roiditis, a high prevalence of goiter was observed (12, 23, 27,
29, 31, 33). However, this was not a universal finding (20, 21),
and iodine intake probably plays a role here. In iodine-
replete areas the thyroid as measured by ultrasonography
does not increase in size during pregnancy (217), while it
does in iodine-deficient areas. This increase is most likely due
to an adaptation to the low environmental iodine, leading to
a more vigorous response of the thyroid to growth stimuli
(218) and exacerbated by the pregnant state (see above).
Apart from this adaptation mechanism, the development of
a goiter in postpartum thyroiditis could be a symptom of the
autoimmune thyroiditis process itself, representing a glan-
dular enlargement due to the lymphocellular infiltration. A
palpable goiter at term was found to be predictive for post-
partum thyroiditis in areas of mild iodine deficiency (33,
219). This was not the case in iodine-sufficient areas (21). A
palpable goiter, however, can be interpreted as a symptom
of preexisting autoimmune thyroiditis. In women with type
I diabetes, Gerstein (40) found that the presence of a goiter
at term was a risk factor for the development of postpartum
thyroiditis. In conclusion, the presence of a goiter most likely
is a symptom of postpartum thyroiditis especially in iodine-
sufficient areas.
Adams et al. (220) studied the ultrasonographic appear-
ance of women at risk of postpartum thyroiditis. Between 4
and 8 wk postpartum, hypoechogenicity was present only in
45% of thyroid antibody-positive women who subsequently
developed postpartum thyroiditis, compared with 17% in
thyroid antibody- positive women in whom thyroid function
remained normal (P  0.05). Hypoechogenicity was present
in only 1.5% of thyroid antibody-negative women (P 
0.001). These observations have recently been extended by
the investigators who found that persistent hypoechogenic-
ity on thyroid ultrasound after the puerperal period indi-
cated an ongoing process of destructive thyroiditis that was
related to the development of permanent hypothyroidism
(221). However, at present, the use of thyroid ultrasound in
the follow up of postpartum thyroiditis is not well docu-
mented. From these studies we conclude that the ultrasound
appearance of postpartum thyroiditis is hypoechogenicity. It
should be noted, however, that 14% of women with TPO
antibodies and postpartum thyroiditis had no ultrasound
hypoechogenicity. Conversely, only 3% of TPO antibody-
negative women without postpartum thyroiditis had ultra-
sound hypoechogenicity, but 39% of women with TPO an-
tibodies but not postpartum thyroiditis did have ultrasound
hypoechogenicity (220). The clinical value of thyroid ultra-
sound in the diagnosis and follow-up of postpartum thy-
roiditis seems therefore limited.
TABLE 4. Association of thyroid antibodies and postpartum thyroiditis with depression
First author
(reference) Yr Country
Inclusion
criteria
No. Included/no.
with psychiatric
assessment
Time of
inclusion and
last psychiatric
assessment
Incidence of
depression
RR of
depressiona
P
value
Association with postpartum thyroiditis (i.e., thyroid dysfunction)
Harris (214) 1989 UK Tab (tab-co’s) 147 (147)/147 (147) 6–8 wk pp/6–8 wk pp 5% (8/147)b 5.2 0.01
Pop (212) 1991 Netherlands Informed consent 303/293 3rd trimester/8 mo pp 21% (61/293)c 1.6 0.02
Kent (25) 1999 Australia Informed consent 748/69 6 mo pp/6 mo pp 11% (8/69)b 1.4 N.S.
Lucas (28) 2000 Spain Informed consent 605/605–444
(1–12 mo pp)
Delivery/12 mo pp 9% (4/45) 0.7 N.S.
Association with thyroid antibodies (normal thyroid function)
Pop (30) 1993 Netherlands Informed consent 303/293 3rd trimester/8 mo pp 21% (61/293)c 1.73 N.S.
Harris (22) 1992 UK Tab (tab-co’s) 145 (229)/110 (132) 2nd trimester/7 mo pp 39% (94/242)c 1.47 N.S.
Kent (25) 1999 Australia Informed consent 748/45 6 mo pp/6 mo pp 11% (5/45)b 1.19 N.S.
Tab, Thyroid antibodies; N.S., not significant.
a Thyroid dysfunction vs. euthyroid, or Tab vs. Tab.
b According to DSM III/DSM III R.
c According to Research Diagnostic Criteria.
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VIII. The Diagnosis, Follow-Up, and Treatment
of a Postpartum Exacerbation of
Autoimmune Thyroiditis
The diagnosis of postpartum thyroiditis must, first, be
based upon a high index of clinical suspicion. Women pre-
senting with nonspecific physical and/or psychological com-
plaints in the first postpartum year should undergo testing
of thyroid function. This should be done by measuring the
serum TSH concentration followed, if abnormal, by deter-
mining the free T4 (fT4) concentration in the same sample.
The differential diagnosis of the thyrotoxicosis comprises
primarily Graves’ disease. Because management and fol-
low-up of postpartum destructive thyrotoxicosis and
Graves’ disease differ, it is important to establish a causal
diagnosis. Clinical features have been discussed in the pre-
vious section; here it is important to note that symptoms and
the presence of a goiter are not helpful in differentiating
postpartum destructive thyrotoxicosis from Graves’ disease.
The presence of ophthalmopathy, however, points to a di-
agnosis of Graves’ disease (222). Diagnosis is further based
on the presence of TSH-R Abs and thyroid scintigraphy (222).
The presence of TSH-R Abs represents Graves’ disease,
which was either unrecognized before pregnancy and re-
lapsed after delivery, or developed de novo after delivery (39,
210). It is important to be aware that thyrotoxicosis in patients
with a previous history of Graves’ disease does not neces-
sarily represent relapse: postpartum thyroiditis can be
superimposed on Graves’ disease (18). Momotani et al. sys-
tematically followed 96 episodes of postpartum hyperthy-
roidism in the first year after delivery in women with a
history of Graves’ disease: in 26 cases radioiodine uptake was
low (10%) during the thyrotoxic phase, indicating destruc-
tive postpartum thyroiditis (19). Indeed, the diagnosis of
postpartum destructive thyrotoxicosis (i.e., postpartum thy-
roiditis) is best established by the presence of a low radio-
iodine uptake. Thyroid scintigraphy should therefore be part
of the diagnostic workup. During breast-feeding, however,
the administration of iodine-131 is contraindicated. When
iodine-123 is used, breast-feeding should be stopped for 3 d
(223, 224). By using technetium (99 mTc) pertechnetate,
interruption of breast-feeding for only 24 h is required
(223, 225).
Serum Tg has been considered as an early indicator of
postpartum thyroiditis (226). But as serum Tg concentrations
are also elevated in nearly all patients with Graves’ disease
(227), the determination of the serum Tg concentration is not
helpful in differentiating postpartum destructive thyrotoxi-
cosis from Graves’ disease. In women with postpartum thy-
roiditis, thyroid ultrasound hypoechogenicity correlates well
with thyroid dysfunction (228). Similar abnormalities, how-
ever, have also been described in Graves’ disease (220). In-
creased IL-6 levels have been found in Graves’ disease and
several thyroid-destructive processes (229, 230). In postpar-
tum thyroiditis, however, IL-6 levels are not different com-
pared with women without postpartum thyroiditis (231).
Therefore, IL-6 measurement could be potentially useful in
the differential diagnosis of postpartum thyrotoxicosis.
However, the routine measurement of IL-6 is currently not
always available.
With regard to the follow-up, permanent hypothyroidism
is the most important sequel of postpartum thyroiditis. Nico-
lai et al. (29) found a prevalence of hypothyroidism of 12%
after 3 yr . Tachi et al. (140) followed 44 Japanese women with
a history of postpartum thyroiditis for a mean interval from
delivery of 8.7 yr (range 5–16 yr) and found 29% of them to
be permanently hypothyroid. In the study by Jansson et al.
(24), the prevalence of hypothyroidism was 30% at the end
of 5 yr. Othman et al. (207) followed 43 patients with post-
partum thyroiditis (90% TPO antibody positive) during a
period of 2–4 yr. Twenty-three percent of the women de-
veloped permanent hypothyroidism compared with none of
171 controls. Very recently, Premawardhana et al. (221) re-
ported a follow-up on 98 TPO-positive women, of whom 48
developed postpartum thyroiditis. During a follow-up pe-
riod of 66–140 months, 24.5% developed (sub)clinical hypo-
thyroidism, whereas only 1.4% of a group of 70 TPO anti-
body-negative controls developed thyroid dysfunction.
Lucas et al. (28) followed 42 patients during a mean period
of 40 months. Five of these 42 women became permanently
hypothyroid. In this study there was no significant difference
in percentage of TPO positivity between women with post-
partum thyroiditis who subsequently became hypothyroid
and those who did not. TPO antibody levels, however, were
higher in those women who developed permanent hypo-
thyroidism. Barca et al. (37) followed 49 women with post-
partum thyroiditis during the second postpartum year and
found 30 of these women to have developed hypothyroidism
at 24 months.
So we can conclude from these studies that permanent
hypothyroidism occurs in 12–61%, a wide variation thus far
unexplained. Differences in definition and variable ascer-
tainment of follow-up may explain this wide variability.
Considering the occurrence of permanent hypothyroid-
ism, studies performed by Roti et al. (232) and Creagh et al.
(233) are of interest. They performed iodide perchlorate dis-
charge tests in women with previous postpartum thyroiditis
and found organification defects in 41% and 64%, respec-
tively. Follow-up in these two studies was 3 to 7 yr. Collec-
tively, the above data show the persistent character of the
underlying thyroid disorder in postpartum thyroiditis and
emphasize the need for a prolonged follow-up, particularly
in TPO-positive women.
Special consideration should be given to women with hy-
pothyroidism antedating pregnancy. An increased need for
T4 during pregnancy is well documented in these women
(175, 232, 234) and after delivery the T4 requirement is pre-
sumed to return to its pregestational level (235). However, it
should be stressed here that in analogy to what has been
described for Graves’ disease, postpartum thyroiditis can
occur in patients with a known previous diagnosis of pri-
mary hypothyroidism, leading to a further decline in thyroid
function. In a recent study, Caixa`s et al. (17) observed dis-
cordance between pregestational and postpartum T4 require-
ments suggestive of postpartum thyroiditis in 12 of 18
patients diagnosed with autoimmune thyroiditis before
pregnancy.
Do patients with postpartum thyroiditis need treatment?
With respect to thyrotoxicosis, we have already pointed out
the importance of an accurate diagnosis. In symptomatic
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cases a short course of -blockade may be beneficial, e.g.,
40–120 mg propranolol or 25–50 mg atenolol daily until
serum fT4 concentrations are normal. Antithyroid drug ther-
apy should obviously not be given because there is no in-
creased thyroid hormone synthesis.
Hypothyroidism should always be treated with T4 replace-
ment therapy. Spontaneous recovery of thyroid function
should not be anticipated (236). Instead, it is reasonable to
stop T4 after 2–6 months to determine whether remission has
occurred (4). If so, we advise discontinuation of treatment
followed by yearly assessment of thyroid function. Others
suggested a pragmatic approach: to maintain the T4 replace-
ment therapy and postpone the cessation of therapy until the
family is complete (237). In discussing T4 replacement ther-
apy with the patient, it is important to realize that T4 ad-
ministration does not always improve the psychological dis-
turbances if present.
IX. Adverse Consequences of Autoimmune
Thyroiditis During Pregnancy and Postpartum
We have discussed postpartum thyroiditis as an acute
stage of autoimmune thyroid destruction—with subsequent
repair—in the context of an existing and ongoing process of
thyroid autosensitization. This process frequently leads to a
gradual development of permanent thyroid failure. The rec-
ognition of the very nature of this process, combined with
recently described detrimental effects of a low thyroid re-
serve due to autoimmune thyroiditis, has important reper-
cussions on clinical practice especially in women of child-
bearing age.
A. Effects of autoimmune thyroiditis on conception
and pregnancy
The relationship between existing thyroid autoimmunity
and the probability of spontaneous abortion has been the
subject of a number of studies. Stagnaro-Green et al. (238)
found that the presence of TPO and/or Tg antibodies in the
first trimester of pregnancy is a risk factor for spontaneous
fetal loss. The authors studied 552 consecutive women in the
first trimester of pregnancy and found that the spontaneous
abortion rate in thyroid antibody-positive women was sig-
nificantly higher than in antibody-negative women (17% vs.
8.4%). These results were confirmed by Glinoer et al. (239)
who found a higher rate of spontaneous abortion in 45
women with thyroid autoantibodies compared with 603 con-
trols: 13.3% vs. 3.3%.
In a prospective study of 54 women who conceived after
in vitro fertilization (IVF) we were unable to find a significant
association between the spontaneous abortion rate and the
presence of TPO antibodies before pregnancy. Although mis-
carriages occurred in 33% of TPO antibody-positive women
and in only 19% of the TPO-negative women, the difference
was not statistically significant (240). Surprisingly, we found
a nearly significant (P  0.05) higher pregnancy rate in the
TPO-positive women compared with the TPO-negative
women. Our results thus contradict those of the two studies
mentioned above, and several biases can be proposed to
explain this discrepancy (241). First, the number of women
with thyroid autoimmunity was low in our study, and the
severity of the thyroid autoimmune process was mild (de-
fined by the presence and cutoff value, respectively, of TPO
antibodies). Second, we determined TPO antibodies before
pregnancy—as opposed to during pregnancy—in women
without a history of habitual abortion. In view of the dis-
cussed immunological changes occurring during pregnancy,
these differences in study design have probably led to an
inclusion of women with less severe forms of thyroid auto-
immunity which might, at least in part, explain the
discrepancy.
It has also been postulated that thyroid autoimmunity and
its consequences influence the timing of miscarriage. Singh
et al. studied 487 women who conceived with assisted re-
productive techniques and found that the presence of thyroid
autoantibodies, measured 14 d after embryo transfer, iden-
tified women at risk of later miscarriage. Later miscarriage
was defined as a miscarriage occurring after clinical recog-
nition of the pregnancy, i.e., after visualization of the gesta-
tional sac by ultrasonography. TPO antibody positivity had
no effect on early, hCG-detected, miscarriage rates (242).
In women with a history of habitual abortion the presence
of non-organ-specific autoantibodies, notably of antiphos-
pholipid and anticardiolipin antibodies, has been associated
with fetal loss (243). Data on the relationship between thyroid
autoantibodies and habitual abortion are conflicting. Several
studies found an association between TPO antibodies and
recurrent first-trimester fetal loss (244–248). However, others
could not confirm this observation (249, 250). Interestingly,
Vaquero et al. (251) have recently investigated the role of mild
thyroid abnormalities in women with thyroid antibodies and
recurrent first-trimester abortions. A total of 42 women with
TPO and/or Tg antibodies and recurrent first-trimester abor-
tions were studied. In this study, treatment with intravenous
Igs was compared with thyroid hormone treatment. The
authors showed that treatment with thyroid hormone was
more effective than treatment with intravenous Igs since 55%
of women with thyroid antibodies treated with intravenous
Igs resulted in live births as compared with 81% live births
in women with thyroid antibodies treated with thyroid hor-
mone. The authors and editors explained these data sug-
gesting that mild degrees of thyroid insufficiency, perhaps at
the level of the female genital tract, not detectable by routine
thyroid testing, and not thyroid autoimmunity per se, is
causal in the earlier mentioned association between the pres-
ence of thyroid antibodies and recurrent abortion (251, 252).
In conclusion, at present there are sufficient data showing
an association of thyroid autoimmunity in early pregnancy
and subsequent miscarriage. However, when taking into
account the conflicting data on the presence of thyroid an-
tibodies and recurrent abortion, the cause of this association,
e.g., a defective immune system failing to become tolerant to
the fetus or mild thyroid insufficiency, remains uncertain.
Taking into consideration the data of Vaquero et al. (251), we
are of the opinion that in women with recurrent miscarriage
and thyroid antibodies, treatment with l-T4 is an option,
although further controlled studies are essential.
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B. Consequences of autoimmune thyroiditis for the offspring
It has become increasingly clear that maternal hypothy-
roxinemia in areas of severe iodine deficiency causes not only
the birth of neurological cretins (253) but is also responsible
for less severe mental deficits (254–257). Notably, the motor
and cognitive impairments of the offspring were associated
with the maternal T4 levels and not with maternal T3 or TSH
levels (258). Moreover, because of their relatively normal T3
levels, these women were not clinically hypothyroid (258).
The association of maternal hypothyroxinemia and neuro-
developmental outcome of the offspring has recently been
extended to populations living in iodine-sufficient areas.
In a recent study by Pop et al. (259), a significant association
between maternal TPO antibody levels at 32 wk gestation
and an IQ loss of 10 points at the age of 4.5 yr in the offspring
was demonstrated. In a follow-up study the authors formu-
lated a hypothesis for this association. The neurodevelop-
ment of 220 children aged 10 months was assessed. Children
born to women with maternal serum fT4 levels below the
tenth percentile at 12 wk gestation (irrespective of elevation
of TSH and/or TPO antibodies) had significantly lower neu-
rodevelopmental scores compared with children of mothers
with higher fT4 values. Women with low fT4 levels at 12 wk
gestation were largely affected by autoimmune thyroiditis,
which can explain the previously found association between
elevated TPO antibody levels at 32 wk gestation and im-
paired child development at 4.5 yr of age (260). However,
there was no correlation between neurodevelopmental
scores of the infants and maternal fT4 at 32 wk gestation,
which is a puzzling finding in view of the expected deteri-
oration in thyroid function during pregnancy in women with
autoimmune thyroiditis (176, 260). Whatever the explanation
for this unexpected finding, the fact remains that after ap-
propriate statistical analysis fT4 levels below the tenth per-
centile at 12 wk gestation represented a significant risk factor
for impaired psychomotor development.
Findings by Pop et al. have been extended by Haddow et
al. (261). These investigators provided evidence that children
born to mothers with hypothyroidism during the second
trimester of pregnancy, as determined by an elevated TSH,
have lower IQ scores and more educational difficulties at age
7–9 yr than children born to mothers with normal TSH levels
during pregnancy. In their study 25,216 serum samples were
prospectively collected, and 47 women with TSH levels at or
above the 99th percentile of the values for all pregnant
women were identified. Additionally, 15 women with TSH
values between the 98th and 99.6th percentiles, and low T4
levels were also included, as were 124 matched controls. The
children of the 62 women with elevated TSH levels during
pregnancy performed less well on all 15 neuropsychological
tests carried out (in 2 of these the difference was significant),
and children had more school difficulties and learning prob-
lems (P  0.06). In this study 77% of the women with hy-
pothyroidism had high titers of TPO antibodies (261). These
data further underline the notion that chronic autoimmune
thyroiditis is the most frequent cause of low normal fT4 levels
and raised TSH levels in these women. Taken together, the
studies by Pop et al. and Haddow et al. provide evidence that
not only overt but also relatively mild and hitherto unrec-
ognized states of thyroid failure are associated with persis-
tent and significant impairment in neuropsychological per-
formance of the offspring.
In a recent publication, Morreale de Escobar et al. (258)
have summarized and discussed present epidemiological
and experimental evidence and argue convincingly that con-
ditions resulting in first-trimester hypothyroxinemia (de-
fined as a low for gestational age circulating maternal free T4,
whether or not TSH is increased) pose an increased risk for
poor neuropsychological development of the fetus. Al-
though we will discuss the issue of screening in Section X of
this review, it is relevant at this point to stress that the effects
of screening and treatment with T4 on the progeny, and the
mothers, needs to be assessed prospectively (and from a strict
scientific point of view placebo-controlled, double-blind) for
efficacy and safety.
We recently observed a decrease in maternal serum fT4
after ovarian hyperstimulation for IVF (262). Considering the
possible importance of fT4 levels for the neuropsychological
development of the offspring, our findings could potentially
have serious implications, and we urge prospective neuro-
psychological studies to be carried out in children born after
IVF. Particularly the offspring of women whose fT4 levels are
already in the low normal range before the start of ovarian
hyperstimulation should be followed, especially in areas of
iodine deficiency and the documented relative hypothyrox-
inemia during pregnancy (175, 263).
C. Consequences of autoimmune thyroiditis for older women
Maternal states of mild thyroid failure due to autoimmune
thyroiditis may lead to serious long-term consequences not
only for the offspring, but also for the women themselves.
First, the risk of permanent clinical thyroid failure is high:
odds ratios as high as 38 have been found (see above) (264).
Second, and probably more importantly, subclinical hypo-
thyroidism may predispose to myocardial infarction and
arterial atherosclerosis. Hak et al. (265) recently showed in a
population-based cross-sectional study of 1,149 women in
Rotterdam, that the population attributable risk of subclin-
ical hypothyroidism for atherosclerosis and myocardial in-
farction is comparable to other known major cardiovascular
risk factors . An association between TPO antibody positivity
per se and atherosclerosis and myocardial infarction was not
found; however, the associations between atherosclerosis
and myocardial infarction and subclinical hypothyroidism
were stronger if thyroid failure was accompanied by the
presence of TPO antibodies (265). These data are at variance
with the 20-yr follow-up of the Whickham survey cohort,
which did not find an association between evidence of auto-
immune thyroiditis (defined as treated hypothyroidism,
presence of thyroid antibodies, or raised TSH) documented
at the first survey with mortality or development of ischemic
heart disease (266). These discrepant findings are most likely
due to differences in study groups (different ages) and def-
initions of autoimmune thyroiditis and hypothyroidism as
well as the initiation of T4 replacement therapy in cases of
hypothyroidism in the Whickham survey (266).
All in all, evidence is accumulating that the early phases
of thyroid autoimmunity, which may not immediately lead
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to clinically overt thyroid failure, have adverse consequences
for the well-being of affected individuals and their offspring.
A mild, but nevertheless relevant, decrement of the thyroid
reserve often accompanies the early phases of thyroid auto-
immunity. This “hidden thyroid failure” becomes more im-
portant when the thyroid needs to perform optimally, such
as during pregnancy and in states when there is an otherwise
heightened risk for atherosclerosis. The occurrence of post-
partum thyroiditis is a clear sign that the thyroid reserve is
under serious autoimmune threat and already considerably
compromised.
The above listed studies provide an incentive to consider
screening for autoimmune thyroiditis to prevent the poten-
tially harmful sequels described above.
X. Screening, What and When?
Screening programs can detect subjects with unsuspected
hypothyroidism or those at risk of developing thyroid dis-
ease or postpartum thyroiditis, but the costs, risks, and ben-
efits of screening for thyroid disorders before and after preg-
nancy must be considered (267). To establish a case for
screening, several criteria must be met. Clear answers to the
following questions are required:
1. Is the prevalence of autoimmune thyroiditis high
enough to justify screening?
2. Is there enough morbidity?
3. Is there an effective way to prevent this morbidity?
4. Are there effective screening tools and when should
these be applied?
5. Is screening cost effective?
Ad. 1) The first question has been dealt with extensively in
Section II of this review. In comparison to other diseases for
which screening is recommended, the prevalence rate of
around 5–7% for thyroid autoimmunity in young women
and a prevalence of elevated TSH levels in pregnant women
as high as 2–3% seems high enough to justify screening in
women of childbearing age (175, 268).
Ad. 2) Considering the morbidity of autoimmune thyroiditis
in women of childbearing age we have discussed that there is:
a. an increased risk of miscarriage;
b. a significant risk of developing hypothyroidism during
gestation;
c. a potential risk for the neuropsychological development
of the offspring;
d. a clearly increased risk of developing postpartum thy-
roiditis; and finally
e. that there is an increased risk for developing permanent
clinically overt hypothyroidism in later life.
In conclusion, the morbidity associated with autoimmune
thyroiditis is considerable.
Ad. 3)
a. Miscarriage. There are now data to suggest that recurrent
miscarriage in women with thyroid antibodies can be pre-
vented by T4 administration (251).
b. Hypothyroidism during gestation. Transition from mild,
subclinical hypothyroidism to overt hypothyroidism in preg-
nancy can be effectively and safely treated with T4.
c. Neuropsychological development of the offspring. It is at
present unknown whether T4 replacement therapy will ef-
fectively prevent detrimental effects on the offspring in these
cases. Clearly, double-blind randomized trails are needed to
clarify this issue (269).
d. Postpartum thyroiditis. There is only one study on the
prevention of postpartum thyroiditis with l-T4 administra-
tion. In this study postpartum treatment of 18 women who
were TPO positive in early pregnancy with l-T4 (0.1 mg daily
from 4–38 wk and 0.05 mg from 39–42 wk postpartum) did
not result in a change in the incidence or time course of
postpartum thyroiditis. However, as expected, the degree of
hypothyroidism was significantly reduced compared with 20
untreated antibody-positive women (maximum TSH 23 vs.
6.9 mU/liter, P 0.05) (194). With regard to other treatment
options, administration of corticosteroids has been described
in a woman with recurring episodes of postpartum thyroid-
itis. Both the hyper- and hypothyroid phases were prevented
(270). However, in general, the effect is small (1), and we
certainly do not recommend this approach as there are no
controlled data and steroids can have serious adverse effects.
e. Permanent hypothyroidism. In women at risk for overt
hypothyroidism l-T4 is an effective and safe preventive
treatment.
Thus, at present, only screening to identify subjects at risk
for hypothyroidism seems indicated. Clearly, a case can be
made for screening of maternal hypothyroxinemia in the first
trimester of pregnancy, but we, and others, are of the opinion
that controlled screening trials should be required before
screening of all pregnant women can be recommended (269).
Ad. 4) What screening tools could be used if the development
of a (pilot)-screening program is considered and when
should these tools be applied?
a. Miscarriage. Because relevant studies have shown an
association of thyroid autoimmunity in early pregnancy and
subsequent miscarriage, measurement of TPO antibodies
could be considered as soon as pregnancy is established.
b and c. Hypothyroidism during pregnancy and neuropsycho-
logical development of the offspring. After publication of the
study by Haddow et al. (261), The Endocrine Society recom-
mended the development of a cost-effective strategy for
screening pregnant women for hypothyroidism before or
early during pregnancy (www.endo-society.org/pubrelations/
pressReleases/archives/1999/hypothyroid.cfm, assessed 23-01-01).
It should be realized that in the studies by Pop et al. and
Haddow et al. neuropsychological development of the in-
fants was associated with fT4 and TSH, respectively. There-
fore, fT4 and TSH are both candidates as screening tools
when developing such a screening program. In view of the
arguments presented by Morreale de Escobar et al. (258) fT4
seems to be the most rational choice (267). Another point to
consider is that whatever screening tool is chosen, cut-off
values need to be established taking into account the differ-
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ent gestational ages (217, 267). This is especially prudent for
TSH as hCG has clear thyrotrophic actions.
What would be the best time for screening? Assuming that
the (mild) hypothyroxinemia itself is responsible for im-
paired neuropsychological development, one would ideally
start to screen fertile women antenatally. However, it seems
unrealistic to expect that we will be able to organize a
prepregnancy screening program. Women cannot, and prob-
ably should not, be expected to consult their physician before
becoming pregnant (176). Screening in early pregnancy is
probably the best that we can accomplish, and screening
algorithms for autoimmune thyroiditis and subclinical and
overt hypothyroidism have already been proposed (176,
271). Interestingly, a screening program in Japan, a country
where the frequency of thyroid disease among pregnant
women may be lower than elsewhere, was initiated in 1986
and by 1997, 70,632 early-pregnant women had been
screened. Screening consisted of TSH, fT4, and Tg antibodies.
Abnormal results were obtained in 2%. The overall incidence
of hyperthyroidism and hypothyroidism was 1 in 413 and 1
in 692 women, respectively. Two-thirds of women with hy-
pothyroidism had evidence of chronic autoimmune thyroid-
itis (272). These data show that a screening program in early
pregnancy is feasible.
d. Postpartum thyroiditis. We have already discussed that
the presence of TPO antibodies in early pregnancy is asso-
ciated with a 30–52% risk of developing subsequent post-
partum thyroiditis (4, 42–44). TPO antibodies in early preg-
nancy could thus be an appropriate screening tool for
development of postpartum thyroiditis.
e. Permanent hypothyroidism. To detect subclinical hypo-
thyroidism it is mandatory to determine TSH and, if ele-
vated, fT4 (preferably from the same blood sample). TPO
antibodies are a powerful risk factor for the transition from
subclinical (elevated TSH and normal fT4) to overt hypothy-
roidism; therefore, the measurement of TPO antibodies, in
our opinion, is also indicated in the case of an elevated TSH
with normal fT4 (264). When considering screening for thy-
roid dysfunction, it should be noted that the American Thy-
roid Association recommends screening with a sensitive se-
rum TSH assay in adults beginning at age 35 yr and every 5
yr thereafter (273). The American College of Physicians is
more conservative: they advise case finding in women older
than 50 yr of age who are seen by primary care physicians
for non-thyroid-related reasons (274, 275).
We stated previously that, considering treatment options,
at present, screening to detect subclinical hypothyroidism
and the transition to overt hypothyroidism seems indicated.
We support, therefore, the recommendations by the Amer-
ican Thyroid Association, but suggest that screening should
be performed earlier in pregnant women.
Ad. 5) We are unaware of long-term prospective studies
addressing the issue of cost-effectiveness for any of the in-
dications discussed here.
If screening programs are set up, the results should be
scientifically evaluated. Before these screening programs are
instituted, case finding is justified, i.e., the identification of
women at risk of autoimmune thyroid disease and its con-
sequences during pregnancy and later in life. Thus, in our
view, TSH determinations should be carried out in young
women with a goiter, type I diabetes, previous postpartum
“depression/blues,” a “thyroid history,” a family history of
thyroid disease, and a personal history of smoking as well as
in women with an induced low fT4 level, i.e., during ovarian
hyperstimulation. If the TSH level is abnormal, the fT4 should
be determined, and in the case of subclinical hypothyroidism
TPO should be determined additionally.
XI. Conclusion
Postpartum thyroiditis is defined as a syndrome of tran-
sient or permanent thyroid dysfunction occurring in the first
year after delivery and based on an autoimmune inflamma-
tion of the thyroid. Classically, a thyrotoxic phase is followed
by a hypothyroid phase. The prevalence of postpartum thy-
roiditis ranges from 5–7%.
In this review, postpartum thyroiditis is conceptualized as
an acute phase of autoimmune thyroid destruction in the
context of an existing and ongoing process of thyroid auto-
sensitization. The following arguments support this view: 1)
the relationship between the occurrence of postpartum thy-
roiditis and the presence of TPO antibodies; 2) the histology
of postpartum thyroiditis (both focal organized and diffuse
destructive lymphocytic thyroiditis with folliculolysis and
disruption); 3) the presence of circulating activated T cells in
postpartum thyroiditis patients; 4) the associations between
the genetic inheritance of MHC molecules and the occurrence
of postpartum thyroiditis; and 5) the fact that postpartum
thyroiditis frequently leads to permanent autoimmune thy-
roid failure.
It is the combination of genetic susceptibility and envi-
ronmental factors that lead to thyroid autoimmunity in gen-
eral and also to postpartum thyroiditis. From pregnancy, an
enhanced state of immune tolerance ensues, leading to an
amelioration of existing thyroid autoimmunity. A rebound
reaction to this pregnancy-associated immune suppression
after delivery explains the aggravation of autoimmune syn-
dromes in the puerperal period, e.g., the occurrence of clin-
ically overt postpartum thyroiditis.
Low thyroid reserve due to autoimmune thyroiditis is
increasingly recognized as a serious health problem, partic-
ularly during pregnancy and postpartum. Existing thyroid
autoimmunity increases the probability of spontaneous fetal
loss. Moreover, there are indications that thyroid failure due
to autoimmune thyroiditis, often mild and subclinical, leads
to permanent and significant impairment in neuropsycho-
logical performance of the offspring. Finally, there is now
emerging evidence that, as women age, subclinical hypo-
thyroidism, as a sequel of postpartum thyroiditis, predis-
poses them to cardiovascular disease. Hence, the concept of
postpartum thyroiditis being a mild and transient disorder
is now changing. The recognition of the true nature of post-
partum thyroiditis, i.e., an acute phase in an ongoing and
chronic thyroid autoimmune process, and the negative con-
sequences such a chronic process can have for offspring of
affected mothers and for the mothers themselves, in the long
run, are reasons to consider screening.
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Designing and performing adequate studies to delineate
screening tools and cost-effectiveness will be the challenge
for the future. Meanwhile, case finding is mandatory. We
think that, at present, there is a good case for treating
subclinical hypothyroidism especially in women of child-
bearing age.
Acknowledgments
The authors would like to thank Dr. P. Perros, Newcastle upon Tyne,
UK, for his critical review of the manuscripts and valuable suggestions.
We have used material obtained in collaborative studies with J. L. Kui-
jpens, V. L. Pop, and W. M. Wiersinga. These colleagues are gratefully
acknowledged for their collaboration and support. Also our laboratory
staff is acknowledged for their excellent technical assistance in the stud-
ies on autoimmune thyroiditis.
This article is dedicated to the memory of Eline M. Berghout.
Address all correspondence and requests for reprints to: A. F. Muller
M.D., Department of Internal Medicine, Diakonessenhuis Utrecht, Bos-
boomstraat 1, 3508 TG, Utrecht, The Netherlands. E-mail: amuller@
diakhuis.nl
Thyroid autoimmune research of the Department of Immunology is
supported by two grants of the Dutch Government Organization NWO
(903-40-167 and 903-40-193).
References
1. Roti E, Emerson CH 1992 Clinical review 29: postpartum thyroid-
itis. J Clin Endocrinol Metab 74:3–5
2. Amino N 1991 Postpartum thyroid disease. In: Bercu BB, Shulman
DI, eds. Advances in perinatal thyroidology. New York: Plenum
Press; 167–180
3. Amino N, Tada H, Hidaka Y 1999 Postpartum autoimmune thy-
roid syndrome: a model of aggravation of autoimmune disease.
Thyroid 9:705–713
4. Hall R 1995 Pregnancy and autoimmune endocrine disease. Bail-
lieres Clin Endocrinol Metab 9:137–155
5. Jansson R, Safwenberg J, Dahlberg PA 1985 Influence of the
HLA-DR4 antigen and iodine status on the development of auto-
immune postpartum thyroiditis. J Clin Endocrinol Metab 60:
168 –173
6. Weetman AP, McGregor AM 1994 Autoimmune thyroid disease:
further developments in our understanding. Endocr Rev 15:
788 – 830
7. Amino N, Miyai K, Kuro R, Tanizawa O, Azukizawa M, Takai S,
Tanaki F, Nishi K, Kawashima M, Kumahara Y 1977 Transient
postpartum hypothyroidism: fourteen cases with autoimmune thy-
roiditis. Ann Intern Med 87:155–159
8. Marqusee E, Hill JA, Mandel SJ 1997 Thyroiditis after pregnancy
loss. J Clin Endocrinol Metab 82:2455–2457
9. Stagnaro-Green A 1992 Post-miscarriage thyroid dysfunction. Ob-
stet Gynecol 80:490–492
10. Roberton HEW 1948 Lassitude, coldness, and hair changes fol-
lowing pregnancy and their response to treatment with thyroid
extract. Br Med J 93:2275–2276
11. Ginsberg J, Walfish PG 1977 Post-partum transient thyrotoxicosis
with painless thyroiditis. Lancet 1:1125–1128
12. Amino N, Mori H, Iwatani Y, Tanizawa O, Kawashima M, Tsuge
I, Ibaragi K, Kumahara Y, Miyai K 1982 High prevalence of tran-
sient post-partum thyrotoxicosis and hypothyroidism. N Engl
J Med 306:849–852
13. Amino N, Miyai K, Yamamoto T, Kuro R, Tanaka F 1977 Transient
recurrence of hyperthyroidism after delivery in Graves’ disease.
J Clin Endocrinol Metab 44:130–136
14. Patel MC, Guneratne N, Haq N, West TE, Weetman AP, Clayton
RN 1995 Peripartum hypopituitarism and lymphocytic hypophy-
sitis. QJM 88:571–580
15. Sheehan HL 1939 Simmond’s disease due to postpartum necrosis
of anterior pituitary. QJM 8:277–309
16. Bevan JS, Othman S, Lazarus JH, Parkes AB, Hall R 1992 Re-
versible adrenocorticotropin deficiency due to probable autoim-
mune hypophysitis in a woman with postpartum thyroiditis. J Clin
Endocrinol Metab 74:548–552
17. Caixas A, Albareda M, Garcia-Patterson A, Rodriguez-Espinosa
J, de Leiva A, Corcoy R 1999 Postpartum thyroiditis in women with
hypothyroidism antedating pregnancy? J Clin Endocrinol Metab
84:4000–4005
18. Eckel RH, Green WL 1980 Postpartum thyrotoxicosis in a patient
with Graves’ disease. Association with low radioactive iodine up-
take. JAMA 243:1454–1456
19. Momotani N, Noh J, Ishikawa N, Ito K 1994 Relationship between
silent thyroiditis and recurrent Graves’ disease in the postpartum
period. J Clin Endocrinol Metab 79:285–289
20. Freeman R, Rosen H, Thysen B 1986 Incidence of thyroid dys-
function in an unselected postpartum population. Arch Intern Med
146:1361–1364
21. Fung HY, Kologlu M, Collison K, John R, Richards CJ, Hall R,
McGregor AM 1988 Postpartum thyroid dysfunction in Mid Glam-
organ. Br Med J 296:241–244
22. Harris B, Othman S, Davies JA, Weppner GJ, Richards CJ, New-
combe RG, Lazarus JH, Parkes AB, Hall R, Phillips DI 1992
Association between postpartum thyroid dysfunction and thyroid
antibodies and depression. Br Med J 305:152–156
23. Hayslip CC, Fein HG, O’Donnell VM, Friedman DS, Klein TA,
Smallridge RC 1988 The value of serum antimicrosomal antibody
testing in screening for symptomatic postpartum thyroid dysfunc-
tion. Am J Obstet Gynecol 159:203–209
24. Jansson R, Bernander S, Karlsson A, Levin K, Nilsson G 1984
Autoimmune thyroid dysfunction in the postpartum period. J Clin
Endocrinol Metab 58:681–687
25. Kent GN, Stuckey BG, Allen JR, Lambert T, Gee V 1999 Post-
partum thyroid dysfunction: clinical assessment and relationship
to psychiatric affective morbidity. Clin Endocrinol (Oxf) 51:
429 – 438
26. Kuijpens JL, Haan-Meulman M, Vader HL, Pop VJ, Wiersinga
WM, Drexhage HA 1998 Cell-mediated immunity and postpartum
thyroid dysfunction: a possibility for the prediction of disease?
J Clin Endocrinol Metab 83:1959–1966
27. Lervang HH, Pryds O, Ostergaard Kristensen HP 1987 Thyroid
dysfunction after delivery: incidence and clinical course. Acta Med
Scand 222:369–374
28. Lucas A, Pizarro E, Granada ML, Salinas I, Foz M, Sanmarti A
2000 Postpartum thyroiditis: epidemiology and clinical evolution
in a nonselected population. Thyroid 10:71–77
29. Nikolai TF, Turney SL, Roberts RC 1987 Postpartum lymphocytic
thyroiditis. Prevalence, clinical course, and long-term follow-up.
Arch Intern Med 147:221–224
30. Pop VJ, de Rooy HA, Vader HL, van der HD, van Son MM,
Komproe IH 1993 Microsomal antibodies during gestation in re-
lation to postpartum thyroid dysfunction and depression. Acta
Endocrinol (Copenh) 129:26–30
31. Rajatanavin R, Chailurkit LO, Tirarungsikul K, Chalayondeja W,
Jittivanich U, Puapradit W 1990 Postpartum thyroid dysfunction
in Bangkok: a geographical variation in the prevalence. Acta En-
docrinol (Copenh) 122:283–287
32. Rasmussen NG, Hornnes PJ, Hoier-Madsen M, Feldt-Rasmussen
U, Hegedus L 1990 Thyroid size and function in healthy pregnant
women with thyroid autoantibodies. Relation to development of
postpartum thyroiditis. Acta Endocrinol (Copenh) 123:395–401
33. Roti E, Bianconi L, Gardini E, Minelli R, De Franco ML, Bacchi
MA, Bresciani D, Villa P, Neri TM, Savi M 1991 Postpartum
thyroid dysfunction in an Italian population residing in an area of
mild iodine deficiency. J Endocrinol Invest 14:669–674
34. Stagnaro-Green A, Roman SH, Cobin RH, el Harazy E, Wallen-
stein S, Davies TF 1992 A prospective study of lymphocyte-initi-
ated immunosuppression in normal pregnancy: evidence of a T-cell
etiology for postpartum thyroid dysfunction. J Clin Endocrinol
Metab 74:645–653
35. Vargas MT, Briones-Urbina R, Gladman D, Papsin FR, Walfish
PG 1988 Antithyroid microsomal autoantibodies and HLA-DR5 are
624 Endocrine Reviews, October 2001, 22(5):605–630 Muller et al. • Consequences of Autoimmune Thyroiditis in Pregnancy
 at Medical Library Erasmus MC on November 20, 2006 edrv.endojournals.orgDownloaded from 
associated with postpartum thyroid dysfunction: evidence sup-
porting an autoimmune pathogenesis. J Clin Endocrinol Metab
67:327–333
36. Walfish PG, Meyerson J, Provias JP, Vargas MT, Papsin FR 1992
Prevalence and characteristics of post-partum thyroid dysfunction:
results of a survey from Toronto, Canada. J Endocrinol Invest
15:265–272
37. Barca MF, Knobel M, Tomimori E, Cardia MS, Medeiros-Neto G
2000 Prevalence and characteristics of postpartum thyroid dys-
function in Sao Paulo, Brazil. Clin Endocrinol (Oxf) 53:21–31
38. Sakaihara M, Yamada H, Kato EH, Ebina Y, Shimada S, Kobashi
G, Fukushi M, Fujimoto S 2000 Postpartum thyroid dysfunction
in women with normal thyroid function during pregnancy. Clin
Endocrinol (Oxf) 53:487–492
39. Gerstein HC 1990 How common is postpartum thyroiditis? A
methodologic overview of the literature. Arch Intern Med 150:
1397–1400
40. Gerstein HC 1993 Incidence of postpartum thyroid dysfunction in
patients with type I diabetes mellitus. Ann Intern Med 118:419–423
41. Alvarez-Marfany M, Roman SH, Drexler AJ, Robertson C, Stagn-
aro-Green A 1994 Long-term prospective study of postpartum
thyroid dysfunction in women with insulin dependent diabetes
mellitus. J Clin Endocrinol Metab 79:10–16
42. Lazarus JH, Othman S 1991 Thyroid disease in relation to preg-
nancy. Clin Endocrinol (Oxf) 34:91–98
43. Lazarus JH 1998 Prediction of postpartum thyroiditis. Eur J En-
docrinol 139:12–13
44. Weetman AP 1994 Prediction of post-partum thyroiditis. Clin En-
docrinol (Oxf) 41:7–8
45. Roitt IM, Doniach D, Campbell PN, Hudson RV 1956 Autoanti-
bodies in Hashimoto’s disease (lymphadenoid goiter). Lancet
2:820–821
46. Amino N, Hagen SR, Yamada N, Refetoff S 1976 Measurement of
circulating thyroid microsomal antibodies by the tanned red cell
haemagglutination technique: its usefulness in the diagnosis of
autoimmune thyroid diseases. Clin Endocrinol (Oxf) 5:115–125
47. Cayzer I, Chalmers SR, Doniach D, Swana G 1978 An evaluation
of two new haemagglutination tests for the rapid diagnosis of
autoimmune thyroid diseases. J Clin Pathol 31:1147–1151
48. Holborow EJ, Brown PC, Roitt IM, Doniach D 1959 Cytoplasmic
localization of complement fixing autoantigen in human thyroid
epithelium. Br J Exp Pathol 40:583–588
49. Trotter WR, Belyavin G, Waddams A 1957 Precipitating and com-
plement fixing antibodies in Hashimoto’s disease. Proc R Soc Med
50:961–962
50. Czarnocka B, Ruf J, Ferrand M, Carayon P, Lissitzky S 1985
Purification of the human thyroid peroxidase and its identification
as the microsomal antigen involved in autoimmune thyroid dis-
eases. FEBS Lett 190:147–152
51. Libert F, Ruel J, Ludgate M, Swillens S, Alexander N, Vassart G,
Dinsart C 1987 Complete nucleotide sequence of the human thy-
roperoxidase-microsomal antigen cDNA. Nucleic Acids Res 15:
6735
52. McLachlan SM, Rapoport B 1992 The molecular biology of thyroid
peroxidase: cloning, expression and role as autoantigen in auto-
immune thyroid disease. Endocr Rev 13:192–206
53. Roitt IM, Ling NR, Doniach D, Couchmann KG 1964 The cyto-
plasmic autoantigen of the human thyroid. I. Immunological and
biochemical characteristics. Immunology 7:375–393
54. Beever K, Bradbury J, Phillips D, McLachlan SM, Pegg C, Goral
A, Overbeck W, Feifel G, Smith BR 1989 Highly sensitive assays
of autoantibodies to thyroglobulin and to thyroid peroxidase. Clin
Chem 35:1949–1954
55. Mc Kenzie JM, Zakarija M 1996 Antibodies in autoimmune thy-
roid disease. In: Braverman LE, Utiger R, eds. Werner and Ingbars
the Thyroid. Philadelphia: Lippincott-Raven Publishers; 416–432
56. Chiovato L, Bassi P, Santini F, Mammoli C, Lapi P, Carayon P,
Pinchera A 1993 Antibodies producing complement-mediated thy-
roid cytotoxicity in patients with atrophic or goitrous autoimmune
thyroiditis. J Clin Endocrinol Metab 77:1700–1705
57. Goodman JW 1994 Antigen presentation & the major histocom-
patibility complex. In: Stites DP, Terr AI, Parslow TG, eds. Basic &
clinical immunology. East Norwalk, CT: Appleton & Lange; 58–65
58. Parkes AB, Othman S, Hall R, John R, Richards CJ, Lazarus JH
1994 The role of complement in the pathogenesis of postpartum
thyroiditis. J Clin Endocrinol Metab 79:395–400
59. Parkes AB, Othman S, Hall R, John R, Lazarus JH 1995 Role of
complement in the pathogenesis of postpartum thyroiditis: rela-
tionship between complement activation and disease presentation
and progression. Eur J Endocrinol 133:210–215
60. Jansson R, Thompson PM, Clark F, McLachlan SM 1986 Associ-
ation between thyroid microsomal antibodies of subclass IgG-1 and
hypothyroidism in autoimmune postpartum thyroiditis. Clin Exp
Immunol 63:80–86
61. Hall R, Fung H, Kologlu M 1988 In: Pinchera A, Ingbar SH,
McKenzie JM, Fenzi GF, eds. Thyroid autoimmunity. New York:
Plenum Press; 211–220
62. Briones-Urbina R, Parkes AB, Bogner U, Mariotti S, Walfish PG
1990 Increase in antimicrosomal antibody-related IgG1 and IgG4,
and titers of antithyroid peroxidase antibodies, but not antibody
dependent cell-mediated cytotoxicity in post-partum thyroiditis
with transient hyperthyroidism. J Endocrinol Invest 13:879–886
63. Weetman AP, Fung HY, Richards CJ, McGregor AM 1990 IgG
subclass distribution and relative functional affinity of thyroid
microsomal antibodies in postpartum thyroiditis. Eur J Clin Invest
20:133–136
64. Hanafusa T, Pujol-Borrell R, Chiovato L, Doniach D, Bottazzo GF
1984 In vitro and in vivo reversal of thyroid epithelial polarity: its
relevance for autoimmune thyroid disease. Clin Exp Immunol 57:
639–646
65. Dussault JH, Letarte J, Guyda H, Laberge C 1980 Lack of influence
of thyroid antibodies on thyroid function in the newborn infant and
on a mass screening program for congenital hypothyroidism. J Pe-
diatr 96:385–389
66. Mariotti S, Sansoni P, Barbesino G, Caturegli P, Monti D, Cos-
sarizza A, Giacomelli T, Passeri G, Fagiolo U, Pinchera A 1992
Thyroid and other organ-specific autoantibodies in healthy cente-
narians. Lancet 339:1506–1508
67. Ruf J, Feldt-Rasmussen U, Hegedus L, Ferrand M, Carayon P 1994
Bispecific thyroglobulin and thyroperoxidase autoantibodies in pa-
tients with various thyroid and autoimmune diseases. J Clin En-
docrinol Metab 79:1404–1409
68. Estienne V, Duthoit C, Costanzo VD, Lejeune PJ, Rotondi M,
Kornfeld S, Finke R, Lazarus JH, Feldt-Rasmussen U, Franke WG,
Smyth P, D’Herbomez M, Conte-Devolx B, Persani L, Carella C,
Jourdain JR, Izembart M, Toubert ME, Pinchera A, Weetman A,
Sapin R, Carayon P, Ruf J 1999 Multicenter study on TGPO au-
toantibody prevalence in various thyroid and non-thyroid diseases;
relationships with thyroglobulin and thyroperoxidase autoanti-
body parameters. Eur J Endocrinol 141:563–569
69. Hara T, Tamai H, Mukuta T, Fukata S, Kuma K 1992 The role of
thyroid stimulating antibody (TSAb) in the thyroid function of
patients with post-partum hypothyroidism. Clin Endocrinol (Oxf)
36:69–74
70. Hidaka Y, Tamaki H, Iwatani Y, Tada H, Mitsuda N, Amino N
1994 Prediction of post-partum Graves’ thyrotoxicosis by measure-
ment of thyroid stimulating antibody in early pregnancy. Clin
Endocrinol (Oxf) 41:15–20
71. Sarlis NJ, Brucker-Davis F, Swift JP, Tahara K, Kohn LD 1997
Graves’ disease following thyrotoxic painless thyroiditis. Analysis
of antibody activities against the thyrotropin receptor in two cases.
Thyroid 7:829–836
72. Shorey S, Badenhoop K, Walfish PG 1998 Graves’ hyperthyroid-
ism after postpartum thyroiditis. Thyroid 8:1117–1122
73. Amino N, Tanizawa O, Mori H, Iwatani Y, Yamada T, Kurachi K,
Kumahara Y, Miyai K 1982 Aggravation of thyrotoxicosis in early
pregnancy and after delivery in Graves’ disease. J Clin Endocrinol
Metab 55:108–112
74. Davies TF 1999 The thyroid immunology of the postpartum period.
Thyroid 9:675–684
75. Tada H, Hidaka Y, Tsuruta E, Kashiwai T, Tamaki H, Iwatani Y,
Amino N 1994 Prevalence of postpartum onset of disease within
patients with Graves’ disease of child-bearing age. Endocr J 41:
325–327
76. Jansson R, Dahlberg PA, Winsa B, Meirik O, Safwenberg J, Karls-
son A 1987 The postpartum period constitutes an important risk for
Muller et al. • Consequences of Autoimmune Thyroiditis in Pregnancy Endocrine Reviews, October 2001, 22(5):605–630 625
 at Medical Library Erasmus MC on November 20, 2006 edrv.endojournals.orgDownloaded from 
the development of clinical Graves’ disease in young women. Acta
Endocrinol (Copenh) 116:321–325
77. Hayslip CC, Baker Jr JR, Wartofsky L, Klein TA, Opsahl MS,
Burman KD 1988 Natural killer cell activity and serum autoanti-
bodies in women with postpartum thyroiditis. J Clin Endocrinol
Metab 66:1089–1093
78. Charreire J 1989 Immune mechanisms in autoimmune thyroiditis.
Adv Immunol 46:263–334
79. Davies TF, Martin A, Concepcion ES, Graves P, Cohen L, Ben
Nun A 1991 Evidence of limited variability of antigen receptors on
intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med
325:238–244
80. Degroot LJ, Quintans J 1989 The causes of autoimmune thyroid
disease. Endocr Rev 10:537–562
81. Martin A, Davies TF 1992 T cells and human autoimmune thyroid
disease: emerging data show lack of need to invoke suppressor T
cell problems. Thyroid 2:247–261
82. Utiger RD 1991 The pathogenesis of autoimmune thyroid disease.
N Engl J Med 325:278–279
83. Weetman AP, McGregor AM 1984 Autoimmune thyroid disease:
developments in our understanding. Endocr Rev 5:309–355
84. Knight SC, Farrant J, Chan J, Bryant A, Bedford PA, Bateman C
1988 Induction of autoimmunity with dendritic cells: studies on
thyroiditis in mice. Clin Immunol Immunopathol 48:277–289
85. Voorby HA, van der Gaag RD, Jeucken PH, Bloot AM, Drexhage
HA 1989 The goitre of the BB/O rat: an animal-model for studying
the role of immunoglobulins stimulating growth of thyroid cells.
Clin Exp Immunol 76:290–295
86. Bernard NF, Ertug F, Margolese H 1992 High incidence of thy-
roiditis and anti-thyroid autoantibodies in NOD mice. Diabetes
41:40–46
87. Hoek A, Schoemaker J, Drexhage HA 1997 Premature ovarian
failure and ovarian autoimmunity. Endocr Rev 18:107–134
88. Kotani T, Umeki K, Hirai K, Ohtaki S 1990 Experimental murine
thyroiditis induced by porcine thyroid peroxidase and its transfer
by the antigen-specific T cell line. Clin Exp Immunol 80:11–18
89. Wick G, Brezinschek HP, Hala K, Dietrich H, Wolf H, Kroemer
G 1989 The obese strain of chickens: an animal model with spon-
taneous autoimmune thyroiditis. Adv Immunol 47:433–500
90. Parker DC 1993 T cell-dependent B cell activation. Annu Rev Im-
munol 11:331–360
91. Mooij P, Drexhage HA 1993 Autoimmune thyroid disease. Clin
Lab Med 13:683–697
92. Chaouat G, Assal MA, Martal J, Raghupathy R, Elliot J, Mosmann
T, Wegmann TG 1995 IL-10 prevents naturally occurring fetal loss
in the CBADBA/2 mating combination, and local defect in IL-10
production in this abortion-prone combination is corrected by in
vivo injection of IFN-. J Immunol 154:4261–4268
93. Raghupathy R 1997 Th1-type immunity is incompatible with suc-
cessful pregnancy. Immunol Today 18:478–482
94. Tang H, Mignon-Godefroy K, Meroni PL, Garotta G, Charreire J,
Nicoletti F 1993 The effects of a monoclonal antibody to interfer-
on- on experimental autoimmune thyroiditis (EAT): prevention of
disease and decrease of EAT-specific T cells. Eur J Immunol 23:
275–278
95. Krammer PH 1999 CD95(APO-1/Fas)-mediated apoptosis: live
and let die. Adv Immunol 71:163–210
96. Tschopp J, Irmler M, Thome M 1998 Inhibition of fas death signals
by FLIPs. Curr Opin Immunol 10:552–558
97. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff
G, Ruberti G, Bagnasco M, Testi R, Galluzzo A 1997 Potential
involvement of Fas and its ligand in the pathogenesis of Hashi-
moto’s thyroiditis. Science 275:960–963
98. Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tseleni-
Balafouta S, Koutras DA, Tsokos M 1998 Fas/Fas ligand up-
regulation and Bcl-2 down-regulation may be significant in the
pathogenesis of Hashimoto’s thyroiditis. J Clin Endocrinol Metab
83:2199–2203
99. Stassi G, Todaro M, Bucchieri F, Stoppacciaro A, Farina F,
Zummo G, Testi R, De Maria R 1999 Fas/Fas ligand-driven T cell
apoptosis as a consequence of ineffective thyroid immunoprivilege
in Hashimoto’s thyroiditis. J Immunol 162:263–267
100. De Maria R, Testi R 1998 Fas-FasL interactions: a common patho-
genetic mechanism in organ-specific autoimmunity. Immunol
Today 19:121–125
101. Stassi G, Di Liberto D, Todaro M, Zeuner A, Ricci-Vitiani L,
Stoppacciaro A, Ruco L, Farina F, Zummo G, De Maria R 2000
Control of target cell survival in thyroid autoimmunity by T helper
cytokines via regulation of apoptotic proteins. Nat Immunol 1:
483–488
102. Roura-Mir C, Catalfamo M, Sospedra M, Alcalde L, Pujol-Borrell
R, Jaraquemada D 1997 Single-cell analysis of intrathyroidal lym-
phocytes shows differential cytokine expression in Hashimoto’s
and Graves’ disease. Eur J Immunol 27:3290–3302
103. Ricci M, Rossi O, Romagnani S, Del Prete GF 1989 Etiologic
factors and pathogenetic aspects of organ-specific autoimmune
diseases. Essential role of autoreactive T cells and lymphokine
network in the activation of effector systems responsible for tissue
lesions. Autoimmunity 2:331–344
104. Kabel PJ, Voorbij HA, Haan-Meulman M, Pals ST, Drexhage HA
1989 High endothelial venules present in lymphoid cell accumu-
lations in thyroids affected by autoimmune disease: a study in men
and BB rats of functional activity and development. J Clin Endo-
crinol Metab 68:744–751
105. Margolick JB, Hsu SM, Volkman DJ, Burman KD, Fauci AS 1984
Immunohistochemical characterization of intrathyroid lympho-
cytes in Graves’ disease. Interstitial and intraepithelial populations.
Am J Med 76:815–821
106. Margolick JB, Weetman AP, Burman KD 1988 Immunohistochem-
ical analysis of intrathyroidal lymphocytes in Graves’ disease: ev-
idence of activated T cells and production of interferon-. Clin
Immunol Immunopathol 47:208–218
107. Matsunaga M, Eguchi K, Fukuda T, Kurata A, Tezuka H, Shi-
momura C, Otsubo T, Ishikawa N, Ito K, Nagataki S 1986 Class
II major histocompatibility complex antigen expression and cellu-
lar interactions in thyroid glands of Graves’ disease. J Clin Endo-
crinol Metab 62:723–728
108. Voorby HA, Kabel PJ, de Haan M, Jeucken PH, van der Gaag RD,
de Baets MH, Drexhage HA 1990 Dendritic cells and class II MHC
expression on thyrocytes during the autoimmune thyroid disease
of the BB rat. Clin Immunol Immunopathol 55:9–22
109. Mizukami Y, Michigishi T, Nonomura A, Hashimoto T, Naka-
mura S, Tonami N, Takazakura E 1993 Postpartum thyroiditis. A
clinical, histologic, and immunopathologic study of 15 cases. Am J
Clin Pathol 100:200–205
110. LiVolsi VA 1993 Postpartum thyroiditis. The pathology slowly
unravels. Am J Clin Pathol 100:193–195
111. Weetman AP, Volkman DJ, Burman KD, Gerrard TL, Fauci AS
1985 The in vitro regulation of human thyrocyte HLA-DR antigen
expression. J Clin Endocrinol Metab 61:817–824
112. Todd I, Pujol-Borrell R, Hammond LJ, Bottazzo GF, Feldmann M
1985 Interferon-gamma induces HLA-DR expression by thyroid
epithelium. Clin Exp Immunol 61:265–273
113. Chan JY, Walfish PG 1986 Activated (Ia) T-lymphocytes and
their subsets in autoimmune thyroid diseases: analysis by dual
laser flow microfluorocytometry. J Clin Endocrinol Metab 62:
403–409
114. Jansson R, Totterman TH, Sallstrom J, Dahlberg PA 1984 Intra-
thyroidal and circulating lymphocyte subsets in different stages of
autoimmune postpartum thyroiditis. J Clin Endocrinol Metab 58:
942–946
115. Robertson MJ, Ritz J 1990 Biology and clinical relevance of human
natural killer cells. Blood 76:2421–2438
116. Kerrebijn JD, Balm AJ, Freeman JL, Dosch HM, Drexhage HA
1999 Who is in control of the immune system in head and neck
cancer? Crit Rev Oncol Hematol 31:31–53
117. Hidaka Y, Amino N, Iwatani Y, Kaneda T, Nasu M, Mitsuda N,
Tanizawa O, Miyai K 1992 Increase in peripheral natural killer cell
activity in patients with autoimmune thyroid disease. Autoimmu-
nity 11:239–246
118. Tamaru M, Matsuura B, Onji M 1999 Increased levels of serum
interleukin-12 in Graves’ disease. Eur J Endocrinol 141:111–116
119. Seaman WE 2000 Natural killer cells and natural killer T cells.
Arthritis Rheum 43:1204–1217
120. Nelson JL 1999 Microchimerism and scleroderma. Curr Rheumatol
Rep 1:15–21
626 Endocrine Reviews, October 2001, 22(5):605–630 Muller et al. • Consequences of Autoimmune Thyroiditis in Pregnancy
 at Medical Library Erasmus MC on November 20, 2006 edrv.endojournals.orgDownloaded from 
121. Weetman AP 1999 The immunology of pregnancy. Thyroid 9:
643–646
122. Klintschar M, Schwaiger P, Mannweiler S, Regauer S, Kleiber M
2001 Evidence of fetal microchimerism in Hashimoto’s thyroiditis.
J Clin Endocrinol Metab 86:2494–2498
123. Abramson J, Stagnaro-Green A 2001 Thyroid antibodies and fetal
loss: an evolving story. Thyroid 11:57–63
124. Imaizumi M, Pritsker A, Unger P, Davies TF 2000 Identification
of fetal cells within the thyroid - potential influence of microchi-
merism on autoimmune thyroiditis. Endocr J 47(Suppl):256
125. Reber PM 1993 Prolactin and immunomodulation. Am J Med 95:
637–644
126. Cross RJ, Campbell JL, Roszman TL 1989 Potentiation of antibody
responsiveness after the transplantation of a syngeneic pituitary
gland. J Neuroimmunol 25:29–35
127. Dardenne M, Savino W, Gagnerault MC, Itoh T, Bach JF 1989
Neuroendocrine control of thymic hormonal production. I. Pro-
lactin stimulates in vivo and in vitro the production of thymulin by
human and murine thymic epithelial cells. Endocrinology 125:3–12
128. Reichlin S 1998 Neuroendocrinology. In: Wilson JD, Foster DW,
Kronenberg HM, Larsen PR, eds. Williams textbook of endocri-
nology. Philadelphia: W.B. Saunders Co; 165–248
129. Brix TH, Kyvik KO, Hegedus L 2000 A population-based study of
chronic autoimmune hypothyroidism in Danish twins. J Clin En-
docrinol Metab 85:536–539
130. Weetman AP 1996 Chronic autoimmune thyroiditis. In: Braverman
LE, Utiger R, eds. Werner and Ingbars the thyroid. Philadelphia:
Lippincott-Raven Publishers; 738–748
131. McLachlan SM, Rapoport B 1996 Genetic factors in thyroid dis-
ease. In: Braverman LE, Utiger R, eds. Werner and Ingbars the
thyroid. Philadelphia: Lippincott-Raven Publishers; 483–496
132. Todd JA, Farrall M 1996 Panning for gold: genome-wide scanning
for linkage in type 1 diabetes. Hum Mol Genet 5 Spec No:1443–1448
133. Tomer Y 2001 Unraveling the genetic susceptibility to autoimmune
thyroid diseases: CTLA-4 takes the stage. Thyroid 11:167–169
134. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, Degroot LJ
1995 CTLA-4 gene polymorphism associated with Graves’ disease
in a Caucasian population. J Clin Endocrinol Metab 80:41–45
135. Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy MI, Kendall-
Taylor P, Pearce SH 1999 Cytotoxic T lymphocyte antigen-4
(CTLA-4) gene polymorphism confers susceptibility to thyroid as-
sociated orbitopathy. Lancet 354:743–744
136. Heward JM, Allahabadia A, Armitage M, Hattersley A, Dodson
PM, Macleod K, Carr-Smith J, Daykin J, Daly A, Sheppard MC,
Holder RL, Barnett AH, Franklyn JA, Gough SC 1999 The devel-
opment of Graves’ disease and the CTLA-4 gene on chromosome
2q33. J Clin Endocrinol Metab 84:2398–2401
137. Allahabadia A 1999 The different approaches to the genetic anal-
ysis of autoimmune thyroid disease. J Endocrinol 163:7–13
138. Kologlu M, Fung H, Darke C, Richards CJ, Hall R, McGregor AM
1990 Postpartum thyroid dysfunction and HLA status. Eur J Clin
Invest 20:56–60
139. Farid NR, Hawe BS, Walfish PG 1983 Increased frequency of
HLA-DR3 and 5 in the syndromes of painless thyroiditis with
transient thyrotoxicosis: evidence for an autoimmune aetiology.
Clin Endocrinol (Oxf) 19:699–704
140. Tachi J, Amino N, Tamaki H, Aozasa M, Iwatani Y, Miyai K 1988
Long term follow-up and HLA association in patients with post-
partum hypothyroidism. J Clin Endocrinol Metab 66:480–484
141. Lervang HH, Pyrds O, Kristensen HP, Jakobsen BK, Svejgaard A
1984 Postpartum autoimmune thyroid disorder associated with
HLA-DR4? Tissue Antigens 23:250–252
142. Thompson C, Farid NR 1985 Post-partum thyroiditis and goitrous
(Hashimoto’s) thyroiditis are associated with HLA-DR4. Immunol
Lett 11:301–303
143. Parkes AB, Darke C, Othman S, Thomas M, Young N, Richards
CJ, Hall R, Lazarus JH 1996 Major histocompatibility complex class
II and complement polymorphisms in postpartum thyroiditis. Eur
J Endocrinol 134:449–453
144. Waterman EA, Watson PF, Lazarus JH, Parkes AB, Darke C,
Weetman AP 1998 A study of the association between a polymor-
phism in the CTLA-4 gene and postpartum thyroiditis. Clin En-
docrinol (Oxf) 49:251–255
145. Berghout A, Wiersinga WM, Smits NJ, Touber JL 1990 Interre-
lationships between age, thyroid volume, thyroid nodularity, and
thyroid function in patients with sporadic nontoxic goiter. Am J
Med 89:602–608
146. Whitacre CC, Reingold SC, O’Looney PA 1999 A gender gap in
autoimmunity. Science 283:1277–1278
147. Wilder RL 1998 Hormones, pregnancy, and autoimmune diseases.
Ann NY Acad Sci 840:45–50
148. Wilder RL 1995 Neuroendocrine-immune system interactions and
autoimmunity. Annu Rev Immunol 13:307–338
149. Homo-Delarche F, Fitzpatrick F, Christeff N, Nunez EA, Bach JF,
Dardenne M 1991 Sex steroids, glucocorticoids, stress and auto-
immunity. J Steroid Biochem Mol Biol 40:619–637
150. Verheul HA, Verveld M, Hoefakker S, Schuurs AH 1995 Effects
of ethinylestradiol on the course of spontaneous autoimmune dis-
ease in NZB/W and NOD mice. Immunopharmacol Immunotoxi-
col 17:163–180
151. Schuurs AH, Verheul HA 1989 Sex hormones and autoimmune
disease. Br J Rheumatol 28(Suppl 1):59–61
152. Giltay EJ, Fonk JC, von Blomberg BM, Drexhage HA, Schalkwijk
C, Gooren LJ 2000 In vivo effects of sex steroids on lymphocyte
responsiveness and immunoglobulin levels in humans. J Clin En-
docrinol Metab 85:1648–1657
153. Formby B 1995 Immunologic response in pregnancy. Its role in
endocrine disorders of pregnancy and influence on the course of
maternal autoimmune diseases. Endocrinol Metab Clin North Am
24:187–205
154. Buyon JP 1998 The effects of pregnancy on autoimmune diseases.
J Leukoc Biol 63:281–287
155. Buyon JP, Nelson JL, Lockshin MD 1996 The effects of pregnancy
on autoimmune diseases. Clin Immunol Immunopathol 78:99–104
156. Da Silva JA, Spector TD 1992 The role of pregnancy in the course
and aetiology of rheumatoid arthritis. Clin Rheumatol 11:189–194
157. Wegmann TG, Lin H, Guilbert L, Mosmann TR 1993 Bidirectional
cytokine interactions in the maternal-fetal relationship: is success-
ful pregnancy a TH2 phenomenon? Immunol Today 14:353–356
158. Szekeres-Bartho J, Wegmann TG 1996 A progesterone-dependent
immunomodulatory protein alters the Th1/Th2 balance. J Reprod
Immunol 31:81–95
159. Krishnan L, Guilbert LJ, Wegmann TG, Belosevic M, Mosmann
TR 1996 T helper 1 response against Leishmania major in pregnant
C57BL/6 mice increases implantation failure and fetal resorptions.
Correlation with increased IFN- and TNF and reduced IL-10 pro-
duction by placental cells. J Immunol 156:653–662
160. Krishnan L, Sad S, Raghupathy R 1995 Characterization of an
immunosuppressive factor secreted by a human trophoblast-
derived choriocarcinoma cell line. Cell Immunol 162:295–308
161. Krishnan L, Guilbert LJ, Russell AS, Wegmann TG, Mosmann
TR, Belosevic M 1996 Pregnancy impairs resistance of C57BL/6
mice to Leishmania major infection and causes decreased antigen-
specific IFN- response and increased production of T helper 2
cytokines. J Immunol 156:644–652
162. Beer AE, Kwak JY, Ruiz JE 1996 Immunophenotypic profiles of
peripheral blood lymphocytes in women with recurrent pregnancy
losses and in infertile women with multiple failed in vitro fertili-
zation cycles. Am J Reprod Immunol 35:376–382
163. Dealtry GB, O’Farrell MK, Fernandez N 2000 The Th2 cytokine
environment of the placenta. Int Arch Allergy Immunol 123:
107–119
164. Mellor AL, Munn DH 1999 Tryptophan catabolism and T-cell
tolerance: immunosuppression by starvation? Immunol Today 20:
469–473
165. Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D,
Munn DH 2001 Prevention of T cell-driven complement activation
and inflammation by tryptophan catabolism during pregnancy.
Nat Immunol 2:64–68
166. Saito S 2000 Cytokine network at the feto-maternal interface. J
Reprod Immunol 47:87–103
167. Piccinni MP, Giudizi MG, Biagiotti R, Beloni L, Giannarini L,
Sampognaro S, Parronchi P, Manetti R, Annunziato F, Livi C 1995
Progesterone favors the development of human T helper cells pro-
ducing Th2-type cytokines and promotes both IL-4 production and
Muller et al. • Consequences of Autoimmune Thyroiditis in Pregnancy Endocrine Reviews, October 2001, 22(5):605–630 627
 at Medical Library Erasmus MC on November 20, 2006 edrv.endojournals.orgDownloaded from 
membrane CD30 expression in established Th1 cell clones. J Im-
munol 155:128–133
168. Laskarin G, Strbo N, Sotosek V, Rukavina D, Faust Z, Szekeres-
Bartho J, Podack ER 1999 Progesterone directly and indirectly
affects perforin expression in cytolytic cells. Am J Reprod Immunol
42:312–320
169. Szekeres-Bartho J, Kilar F, Falkay G, Csernus V, Torok A, Pacsa
AS 1985 The mechanism of the inhibitory effect of progesterone on
lymphocyte cytotoxicity: I. Progesterone-treated lymphocytes re-
lease a substance inhibiting cytotoxicity and prostaglandin syn-
thesis. Am J Reprod Immunol Microbiol 9:15–18
170. Faust Z, Laskarin G, Rukavina D, Szekeres-Bartho J 1999 Pro-
gesterone-induced blocking factor inhibits degranulation of natural
killer cells. Am J Reprod Immunol 42:71–75
171. Szekeres-Bartho J, Autran B, Debre P, Andreu G, Denver L, Cha-
ouat G 1989 Immunoregulatory effects of a suppressor factor from
healthy pregnant women’s lymphocytes after progesterone induc-
tion. Cell Immunol 122:281–294
172. Szekeres-Bartho J, Par G, Szereday L, Smart CY, Achatz I 1997
Progesterone and non-specific immunologic mechanisms in preg-
nancy. Am J Reprod Immunol 38:176–182
173. Gilmore W, Weiner LP, Correale J 1997 Effect of estradiol on
cytokine secretion by proteolipid protein-specific T cell clones iso-
lated from multiple sclerosis patients and normal control subjects.
J Immunol 158:446–451
174. Glinoer D, Riahi M, Grun JP, Kinthaert J 1994 Risk of subclinical
hypothyroidism in pregnant women with asymptomatic autoim-
mune thyroid disorders. J Clin Endocrinol Metab 79:197–204
175. Glinoer D 1997 The regulation of thyroid function in pregnancy:
pathways of endocrine adaptation from physiology to pathology.
Endocr Rev 18:404–433
176. Glinoer D, Delange F 2000 The potential repercussions of mater-
nal, fetal, and neonatal hypothyroxinemia on the progeny. Thyroid
10:871–887
177. Drexhage HA 1993 Autoimmunity and thyroid diseases. In: Mo-
naco F, Satta MA, Shapiro B, Troncone L, eds. Thyroid diseases:
clinical fundamentals and therapy. Boca Raton, FL: CRC Press, Inc;
491–505
178. Tajiri J, Higashi K, Morita M, Umeda T, Sato T 1986 Studies of
hypothyroidism in patients with high iodine intake. J Clin Endo-
crinol Metab 63:412–417
179. Kahaly GJ, Dienes HP, Beyer J, Hommel G 1998 Iodide induces
thyroid autoimmunity in patients with endemic goitre: a random-
ised, double-blind, placebo-controlled trial. Eur J Endocrinol 139:
290–297
180. Boukis MA, Koutras DA, Souvatzoglou A, Evanglopoulou A,
Vrontakis M, Karaiskos KS, Piperingos GD, Kitsopanidis J, Mou-
lopoulos SD 1985 Iodine-induced autoimmunity. In: Hall R, Kob-
berling J, eds. Thyroid disorders associated with iodine deficiency
and excess. New York: Raven Press; 217–221
181. Doufas AG, Mastorakos G, Chatziioannou S, Tseleni-Balafouta
S, Piperingos G, Boukis MA, Mantzos E, Caraiskos CS, Mantzos
J, Alevizaki M, Koutras DA 1999 The predominant form of non-
toxic goiter in Greece is now autoimmune thyroiditis. Eur J En-
docrinol 140:505–511
182. Boukis MA, Koutras DA, Souvatzoglou A, Evangelopoulou A,
Vrontakis M, Moulopoulos SD 1983 Thyroid hormone and im-
munological studies in endemic goiter. J Clin Endocrinol Metab
57:859–862
183. Tsatsoulis A, Johnson EO, Andricula M, Kalogera C, Svarna E,
Spyroy P, Seferiadis K, Tsolas O 1999 Thyroid autoimmunity is
associated with higher urinary iodine concentrations in an iodine-
deficient area of Northwestern Greece. Thyroid 9:279–283
184. Laurberg P, Nohr SB, Pedersen KM, Hreidarsson AB, Andersen
S, Bulow P, I, Knudsen N, Perrild H, Jorgensen T, Ovesen L 2000
Thyroid disorders in mild iodine deficiency. Thyroid 10:951–963
185. Allen EM, Appel MC, Braverman LE 1986 The effect of iodide
ingestion on the development of spontaneous lymphocytic thy-
roiditis in the diabetes-prone BB/W rat. Endocrinology 118:1977–
1981
186. Bagchi N, Brown TR, Urdanivia E, Sundick RS 1985 Induction of
autoimmune thyroiditis in chickens by dietary iodine. Science 230:
325–327
187. Many MC, Maniratunga S, Denef JF 1996 The non-obese diabetic
(NOD) mouse: an animal model for autoimmune thyroiditis. Exp
Clin Endocrinol Diabetes 104(Suppl 3):17–20
188. Bagchi N, Brown TR, Sundick RS 1995 Thyroid cell injury is an
initial event in the induction of autoimmune thyroiditis by iodine
in obese strain chickens. Endocrinology 136:5054–5060
189. Many MC, Mestdagh C, van den Hove MF, Denef JF 1992 In vitro
study of acute toxic effects of high iodide doses in human thyroid
follicles. Endocrinology 131:621–630
190. Sundick RS, Herdegen DM, Brown TR, Bagchi N 1987 The in-
corporation of dietary iodine into thyroglobulin increases its im-
munogenicity. Endocrinology 120:2078–2084
191. Ebner SA, Lueprasitsakul W, Alex S, Fang SL, Appel MC, Braver-
man LE 1992 Iodine content of rat thyroglobulin affects its anti-
genicity in inducing lymphocytic thyroiditis in the BB/Wor rat.
Autoimmunity 13:209–214
192. Rose NR, Rasooly L, Saboori AM, Burek CL 1999 Linking iodine
with autoimmune thyroiditis. Environ Health Perspect 107:
749–752
193. Othman S, Phillips DI, Lazarus JH, Parkes AB, Richards C, Hall
R 1992 Iodine metabolism in postpartum thyroiditis. Thyroid
2:107–111
194. Kampe O, Jansson R, Karlsson FA 1990 Effects of L-thyroxine and
iodide on the development of autoimmune postpartum thyroiditis.
J Clin Endocrinol Metab 70:1014–1018
195. Nøhr SB, Jorgensen A, Pedersen KM, Laurberg P 2000 Postpartum
thyroid dysfunction in pregnant thyroid peroxidase antibody-
positive women living in an area with mild to moderate iodine
deficiency: is iodine supplementation safe? J Clin Endocrinol Metab
85:3191–3198
196. Langer P, Tajtakova M, Fodor G, Kocan A, Bohov P, Michalek J,
Kreze A 1998 Increased thyroid volume and prevalence of thyroid
disorders in an area heavily polluted by polychlorinated biphenyls.
Eur J Endocrinol 139:402–409
197. Maloof F, Soodak M 1966 Oxidation of thiocyanate, another index
of thyroid function. Endocrinology 78:1198–1204
198. Ohtaki S, Rosenberg IN 1971 Prompt stimulation by TSH of thy-
roid oxidation by thiocyanate. Endocrinology 88:566
199. Greer MA, Stott AK, Milne KA 1966 Effects of thiocyanate, per-
chlorate and other anions on thyroidal iodine metabolism. Endo-
crinology 79:237–247
200. Fukayama H, Nasu M, Murakami S, Sugawara M 1992 Exami-
nation of antithyroid effects of smoking products in cultured thy-
roid follicles: only thiocyanate is a potent antithyroid agent. Acta
Endocrinol (Copenh) 127:520–525
201. Morris DR, Hager LP 1966 Mechanism of the inhibition of enzy-
matic halogenation by antithyroid agents. J Biol Chem 241:3582–
3589
202. Virion A, Deme D, Pommier J, Nunez J 1980 Opposite effects of
thiocyanate on tyrosine iodination and thyroid hormone synthesis.
Eur J Biochem 112:1–7
203. Christensen SB, Ericsson UB, Janzon L, Tibblin S, Melander A
1984 Influence of cigarette smoking on goiter formation, thyro-
globulin, and thyroid hormone levels in women. J Clin Endocrinol
Metab 58:615–618
204. Prummel MF, Wiersinga WM 1993 Smoking and risk of Graves’
disease. JAMA 269:479–482
205. Shine B, Fells P, Edwards OM, Weetman AP 1990 Association
between Graves’ ophthalmopathy and smoking. Lancet 335:1261–
1263
206. Brix TH, Hansen PS, Kyvik KO, Hegedus L 2000 Cigarette smok-
ing and risk of clinically overt thyroid disease: a population-based
twin case-control study. Arch Intern Med 160:661–666
207. Othman S, Phillips DI, Parkes AB, Richards CJ, Harris B, Fung
H, Darke C, John R, Hall R, Lazarus JH 1990 A long-term
follow-up of postpartum thyroiditis. Clin Endocrinol (Oxf) 32:
559 –564
208. Kuijpens JL, Pop VJ, Vader HL, Drexhage HA, Wiersinga WM
1998 Prediction of post partum thyroid dysfunction: can it be im-
proved? Eur J Endocrinol 139:36–43
209. Lazarus JH, Ammari F, Oretti R, Parkes AB, Richards CJ, Harris
B 1997 Clinical aspects of recurrent postpartum thyroiditis. Br J Gen
Pract 47:305–308
628 Endocrine Reviews, October 2001, 22(5):605–630 Muller et al. • Consequences of Autoimmune Thyroiditis in Pregnancy
 at Medical Library Erasmus MC on November 20, 2006 edrv.endojournals.orgDownloaded from 
210. Jansson R, Dahlberg PA, Karlsson FA 1988 Postpartum thyroid-
itis. Baillieres Clin Endocrinol Metab 2:619–635
211. Lazarus JH, Hall R, Othman S, Parkes AB, Richards CJ, McCul-
loch B, Harris B 1996 The clinical spectrum of postpartum thyroid
disease. QJM 89:429–435
212. Pop VJ, de Rooy HA, Vader HL, van der HD, van Son M, Komproe
IH, Essed GG, de Geus CA 1991 Postpartum thyroid dysfunction
and depression in an unselected population [published erratum
appears in N Engl J Med 1991 Aug 1;325(5):371]. N Engl J Med
324:1815–1816
213. Nikolai TF, Coombs GJ, McKenzie AK 1981 Lymphocytic thy-
roiditis with spontaneously resolving hyperthyroidism and sub-
acute thyroiditis. Long-term follow-up. Arch Intern Med 141:1455–
1458
214. Harris B, Fung H, Johns S, Kologlu M, Bhatti R, McGregor AM,
Richards CJ, Hall R 1989 Transient post-partum thyroid dysfunc-
tion and postnatal depression. J Affect Disord 17:243–249
215. Cleare AJ, McGregor A, O’Keane V 1995 Neuroendocrine evi-
dence for an association between hypothyroidism, reduced central
5-HT activity and depression. Clin Endocrinol (Oxf) 43:713–719
216. Cleare AJ, McGregor A, Chambers SM, Dawling S, O’Keane V
1996 Thyroxine replacement increases central 5-hydroxytrypta-
mine activity and reduces depressive symptoms in hypothyroid-
ism. Neuroendocrinology 64:65–69
217. Berghout A, Endert E, Ross A, Hogerzeil HV, Smits NJ, Wiersinga
WM 1994 Thyroid function and thyroid size in normal pregnant
women living in an iodine replete area. Clin Endocrinol (Oxf)
41:375–379
218. Berghout A, Wiersinga W 1998 Thyroid size and thyroid function
during pregnancy: an analysis. Eur J Endocrinol 138:536–542
219. Fardella C, Lopez JM, Valdes ME, Nunez M, Miranda M 1990
Autoimmune thyroid disease in the puerperium. Predictive value
of thyroid enlargement and related hormonal changes occurring
during pregnancy. J Endocrinol Invest 13:283–286
220. Adams H, Jones MC, Othman S, Lazarus JH, Parkes AB, Hall R,
Phillips DI, Richards CJ 1992 The sonographic appearances in
postpartum thyroiditis. Clin Radiol 45:311–315
221. Premawardhana LD, Parkes AB, Ammari F, John R, Darke C,
Adams H, Lazarus JH 2000 Postpartum thyroiditis and long-term
thyroid status: prognostic influence of thyroid peroxidase antibod-
ies and ultrasound echogenicity. J Clin Endocrinol Metab 85:71–75
222. Kendall-Taylor P 1995 Investigation of thyrotoxicosis. Clin Endo-
crinol (Oxf) 42:309–313
223. Cavalieri RR, McDougall IR 1996 In vivo isotopic tests and im-
aging. In: Braverman LE, Utiger R (eds) Werner and Ingbars the
thyroid. Philadelphia: Lippincott-Raven Publishers; 352–376
224. Romney BM, Nickoloff EL, Esser PD, Alderson PO 1986 Radio-
nuclide administration to nursing mothers: mathematically de-
rived guidelines. Radiology 160:549–554
225. Lervang HH, Askaa S, Ostergaard Kristensen HP 1987 Techne-
tium Tc 99 m uptake in postpartum thyrotoxicosis. Arch Intern Med
147:994, 997
226. Parkes AB, Black EG, Adams H, John R, Richards CJ, Hall R,
Lazarus JH 1994 Serum thyroglobulin: an early indicator of auto-
immune post-partum thyroiditis. Clin Endocrinol (Oxf) 41:9–14
227. Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri
R, Ingbar SH 1988 The role of thyroid-stimulating antibodies of
Graves’ disease in differentiated thyroid cancer. N Engl J Med
318:753–759
228. Parkes AB, Adams H, Othman S, Hall R, John R, Lazarus JH 1996
The role of complement in the pathogenesis of postpartum thy-
roiditis: ultrasound echogenicity and the degree of complement-
induced thyroid damage. Thyroid 6:177–182
229. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N,
Minelli R, Braverman LE, Roti E 1996 Increased serum concen-
trations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients
with Graves’ disease. J Clin Endocrinol Metab 81:2976–2979
230. Bartalena L, Brogioni S, Grasso L, Rago T, Vitti P, Pinchera A,
Martino E 1994 Interleukin-6: a marker of thyroid-destructive pro-
cesses? J Clin Endocrinol Metab 79:1424–1427
231. Ahmad L, Parkes A, Lazarus J, Bartalena L, Martino E, Diamond
E, Stagnaro-Green A 1998 Interleukin-6 levels are not increased in
women with postpartum thyroid dysfunction. Thyroid 8:371–375
232. Roti E, Minelli R, Gardini E, Bianconi L, Neri T, Gavaruzzi G,
Ugolotti G, Salvo D, Braverman LE 1991 Impaired intrathyroidal
iodine organification and iodine-induced hypothyroidism in eu-
thyroid women with a previous episode of postpartum thyroiditis.
J Clin Endocrinol Metab 73:958–963
233. Creagh FM, Parkes AB, Lee A, Adams H, Hall R, Richards CJ,
Lazarus JH 1994 The iodide perchlorate discharge test in women
with previous post-partum thyroiditis: relationship to sonographic
appearance and thyroid function. Clin Endocrinol (Oxf) 40:765–768
234. Mandel SJ, Larsen PR, Seely EW, Brent GA 1990 Increased need
for thyroxine during pregnancy in women with primary hypothy-
roidism. N Engl J Med 323:91–96
235. Mestman JH, Goodwin TM, Montoro MM 1995 Thyroid disorders
of pregnancy. Endocrinol Metab Clin North Am 24:41–71
236. Stuckey BG, Kent GN, Allen JR 2001 The biochemical and clinical
course of postpartum thyroid dysfunction: the treatment decision.
Clin Endocrinol (Oxf) 54:377–383
237. Stagnaro-Green A 2000 Recognizing, understanding, and treating
postpartum thyroiditis. Endocrinol Metab Clin North Am 29:
417–430
238. Stagnaro-Green A, Roman SH, Cobin RH, el Harazy E, Alvarez-
Marfany M, Davies TF 1990 Detection of at-risk pregnancy by
means of highly sensitive assays for thyroid autoantibodies. JAMA
264:1422–1425
239. Glinoer D, Soto MF, Bourdoux P, Lejeune B, Delange F, Lemone
M, Kinthaert J, Robijn C, Grun JP, De Nayer P 1991 Pregnancy in
patients with mild thyroid abnormalities: maternal and neonatal
repercussions. J Clin Endocrinol Metab 73:421–427
240. Muller AF, Verhoeff A, Mantel MJ, Berghout A 1999 Thyroid
autoimmunity and abortion: a prospective study in women un-
dergoing in vitro fertilization. Fertil Steril 71:30–34
241. Glinoer D 1999 Thyroid autoimmunity and spontaneous abortion.
Fertil Steril 72:373–374
242. Singh A, Dantas ZN, Stone SC, Asch RH 1995 Presence of thyroid
antibodies in early reproductive failure: biochemical vs. clinical
pregnancies. Fertil Steril 63:277–281
243. Cowchock S, Smith JB, Gocial B 1986 Antibodies to phospholipids
and nuclear antigens in patients with repeated abortions. Am J
Obstet Gynecol 155:1002–1010
244. Roberts J, Jenkins C, Wilson R, Pearson C, Franklin IA, MacLean
MA, McKillop JH, Walker JJ 1996 Recurrent miscarriage is asso-
ciated with increased numbers of CD5/20 positive lymphocytes
and an increased incidence of thyroid antibodies. Eur J Endocrinol
134:84–86
245. Pratt DE, Kaberlein G, Dudkiewicz A, Karande V, Gleicher N
1993 The association of antithyroid antibodies in euthyroid non-
pregnant women with recurrent first trimester abortions in the next
pregnancy. Fertil Steril 60:1001–1005
246. Kutteh WH, Yetman DL, Carr AC, Beck LA, Scott Jr RT 1999
Increased prevalence of antithyroid antibodies identified in women
with recurrent pregnancy loss but not in women undergoing as-
sisted reproduction. Fertil Steril 71:843–848
247. Mecacci F, Parretti E, Cioni R, Lucchetti R, Magrini A, La Torre
P, Mignosa M, Acanfora L, Mello G 2000 Thyroid autoimmunity
and its association with non-organ-specific antibodies and sub-
clinical alterations of thyroid function in women with a history of
pregnancy loss or preeclampsia. J Reprod Immunol 46:39–50
248. Bussen SS, Steck T 1997 Thyroid antibodies and their relation to
antithrombin antibodies, anticardiolipin antibodies and lupus an-
ticoagulant in women with recurrent spontaneous abortions (an-
tithyroid, anticardiolipin and antithrombin autoantibodies and lu-
pus anticoagulant in habitual aborters). Eur J Obstet Gynecol
Reprod Biol 74:139–143
249. Esplin MS, Branch DW, Silver R, Stagnaro-Green A 1998 Thyroid
autoantibodies are not associated with recurrent pregnancy loss.
Am J Obstet Gynecol 179:1583–1586
250. Rushworth FH, Backos M, Rai R, Chilcott IT, Baxter N, Regan L
2000 Prospective pregnancy outcome in untreated recurrent mis-
carriers with thyroid autoantibodies. Hum Reprod 15:1637–1639
251. Vaquero E, Lazzarin N, De Carolis C, Valensise H, Moretti C,
Ramanini C 2000 Mild thyroid abnormalities and recurrent spon-
taneous abortion: diagnostic and therapeutical approach. Am J
Reprod Immunol 43:204–208
Muller et al. • Consequences of Autoimmune Thyroiditis in Pregnancy Endocrine Reviews, October 2001, 22(5):605–630 629
 at Medical Library Erasmus MC on November 20, 2006 edrv.endojournals.orgDownloaded from 
252. Glinoer D 2000 Thyroid immunity, thyroid dysfunction, and the
risk of miscarriage: a propos article by Vaquero et al. Mild thyroid
abnormalities and recurrent spontaneous abortion: diagnostic and
therapeutical approach. Am J Reprod Immunol 43:202–203
253. Choufoer JC, van Rhijn M, Querido A 1965 Endemic goiter in
Western New Guinea. II. Clinical picture, incidence and patho-
genesis of endemic cretinism. J Clin Endocrinol Metab 25:385–402
254. Man EB, Holden RH, Jones WS 1971 Thyroid function in human
pregnancy. VII. Development and retardation of 4-year-old prog-
eny of euthyroid and of hypothyroxinemic women. Am J Obstet
Gynecol 109:12–19
255. Man EB 1972 Thyroid function in pregnancy and infancy. Maternal
hypothyroxinemia and retardation of progeny. CRC Crit Rev Clin
Lab Sci 3:203–225
256. Man EB, Serunian SA 1976 Thyroid function in human pregnancy.
IX. Development or retardation of 7-year-old progeny of hypothy-
roxinemic women. Am J Obstet Gynecol 125:949
257. Man EB, Brown JF, Serunian SA 1991 Maternal hypothyroxine-
mia: psychoneurological deficits of progeny. Ann Clin Lab Sci
21:227–239
258. Morreale dE, Obregon MJ, Escobar dR 2000 Is neuropsychological
development related to maternal hypothyroidism or to maternal
hypothyroxinemia? J Clin Endocrinol Metab 85:3975–3987
259. Pop VJ, de Vries E, van Baar AL, Waelkens JJ, de Rooy HA,
Horsten M, Donkers MM, Komproe IH, van Son MM, Vader HL
1995 Maternal thyroid peroxidase antibodies during pregnancy: a
marker of impaired child development? J Clin Endocrinol Metab
80:3561–3566
260. Pop VJ, Kuijpens JL, van Baar AL, Verkerk G, van Son MM, de
Vijlder JJ, Vulsma T, Wiersinga WM, Drexhage HA, Vader HL
1999 Low maternal free thyroxine concentrations during early
pregnancy are associated with impaired psychomotor develop-
ment in infancy. Clin Endocrinol (Oxf) 50:149–155
261. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ,
Gagnon J, O’Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix
JD, Klein RZ 1999 Maternal thyroid deficiency during pregnancy
and subsequent neuropsychological development of the child.
N Engl J Med 341:549–555
262. Muller AF, Verhoeff A, Mantel MJ, De Jong FH, Berghout A 2000
Decrease of free thyroxine levels after controlled ovarian hyper-
stimulation. J Clin Endocrinol Metab 85:545–548
263. Glinoer D, Delange F, Laboureur I, De Nayer P, Lejeune B,
Kinthaert J, Bourdoux P 1992 Maternal and neonatal thyroid func-
tion at birth in an area of marginally low iodine intake. J Clin
Endocrinol Metab 75:800–805
264. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates
D, Clark F, Grimley EJ, Hasan DM, Rodgers H, Tunbridge F 1995
The incidence of thyroid disorders in the community: a twenty-year
follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 43:55–68
265. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman
JC 2000 Subclinical hypothyroidism is an independent risk factor
for atherosclerosis and myocardial infarction in elderly women: the
Rotterdam Study. Ann Intern Med 132:270–278
266. Tunbridge WM, Vanderpump MP 2000 Population screening for
autoimmune thyroid disease. Endocrinol Metab Clin North Am
29:239–253
267. Smallridge RC, Ladenson PW 2001 Hypothyroidism in pregnancy:
consequences to neonatal health. J Clin Endocrinol Metab 86:2349–
2353
268. Klein RZ, Haddow JE, Faix JD, Brown RS, Hermos RJ, Pulkkinen
A, Mitchell ML 1991 Prevalence of thyroid deficiency in pregnant
women. Clin Endocrinol (Oxf) 35:41–46
269. Pop VJ, van Baar AL, Vulsma T 1999 Should all pregnant women
be screened for hypothyroidism? Lancet 354:1224–1225
270. Amino N 1984 Mechanism of postpartum thyroid disease. Pro-
ceedings of the 7th International Congress of Endocrinology:
461–464
271. Glinoer D 1998 The systematic screening and management of
hypothyroidism and hyperthyroidism during pregnancy. Trends
Endocrinol Metab 10:403–411
272. Fukushi M, Honma K, Fujita K 1999 Maternal thyroid deficiency
during pregnancy and subsequent neuropsychological develop-
ment of the child. N Engl J Med 341:2016
273. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG,
Smith SA, Daniels GH 2000 American Thyroid Association guide-
lines for detection of thyroid dysfunction. Arch Intern Med 160:
1573–1575
274. Helfand M, Redfern CC 1998 Clinical guideline, part 2. Screening
for thyroid disease: an update. American College of Physicians
[published erratum appears in Ann Intern Med 1999 Feb 2;130(3):
246]. Ann Intern Med 129:144–158
275. Helfand M, Crapo LM 1990 Screening for thyroid disease. Ann
Intern Med 112:840–849
22–25 April 2002
First International Congress on Transthyretin (Prealbumin)
in Health and Disease
Palais de la Musique et des Congre`s, Strasbourg, France. Web site: www.strasbourgmeeting.com
Scientific Secretariat: Yves Ingenbleek, Fax: (33) 388. 67. 09. 64; E-mail: ingen@pharma.u-strasbg.fr
Abstract deadline: November 15, 2001.
Congress and hotel registration deadlines: January 15, 2002.
630 Endocrine Reviews, October 2001, 22(5):605–630 Muller et al. • Consequences of Autoimmune Thyroiditis in Pregnancy
 at Medical Library Erasmus MC on November 20, 2006 edrv.endojournals.orgDownloaded from 
